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Abstract 
This work focuses on development of IVIVCs for variety of Q1/Q2 equivalent parenteral PLGA 
microspheres with different physicochemical and release characteristics to: 1) achieve a 
comprehensive understanding of impact of minor manufacturing changes on the physicochemical 
properties of the microspheres and their relationship with in vitro and in vivo performance; 2) 
establish Level A IVIVCs; and 3) determine whether release characteristic differences between 
microspheres can affect the development and predictability of IVIVCs for a variety of 
microsphere drug products. 
Naltrexone and leuprolide acetate (LA) were chosen as the small molecule and peptide 
microsphere model drug product, respectively. Significant differences were observed in the 
physicochemical properties (such as particle size, porosity, and morphology) and release 
characteristics (such as rate and duration) of the compositionally equivalent naltrexone and LA 
microspheres formulations prepared with minor manufacturing changes. In addition, significant 
differences in the in vitro burst release and the impact of pore diameter/structure on the release 
rate were observed for the prepared peptide microsphere formulations. An accelerated in vitro 
release testing method using modified USP apparatus 4 was developed as a quality control tool 
for naltrexone microspheres. 
The in vivo release profiles of microspheres obtained using a rabbit model were deconvoluted 
using the Loo-Riegelman method, and compared with the respective in vitro release profiles. The 
in vivo release profiles showed the same rank order as the in vitro release profiles but with 
Janki Andhariya– University of Connecticut, [2019] 
 overall faster in vivo release rates. In addition, LA microspheres had significantly low in vivo 
burst release, which is considered to be due to the masking effect of the absorption phase from 
the intramuscular site, and this was shown to complicate the development of an IVIVC. Despite 
these challenges, affirmative Level A IVIVCs were successfully developed for both microsphere 
products.  
Moreover, Level A IVIVCs with the ability to predict various types of burst release were 
developed for the compositionally equivalent risperidone and LA microspheres. It was observed 
that IVIVCs developed using formulations with less variation in burst release had better 
predictability and vice-versa.  
This work provides a comprehensive understanding of developing IVIVCs for complex 
parenteral drug products such as microspheres.  
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Polymeric microsphere products have become increasingly important as a means to 
deliver drugs in a controlled manner over longer periods of time for both systemic and local 
delivery.1-3 Moreover, microspheres can be formulated into injectable dosage forms that facilitate 
administration and therefore patient compliance compared to bulky drug delivery 
implants/devices. There are currently seventeen FDA-approved parenteral microsphere products 
on the market for use as depot formulations4. Poly(lactic-co-glycolic acid) (PLGA) is the 
predominant polymeric carrier for FDA approved parenteral injectable microspheres. In addition, 
PLGA is used in many other FDA-approved medicines and devices mainly due to its 
biodegradability, biocompatibility, and resorbability (through natural pathways)5,6. Moreover, the 
rate and onset of PLGA degradation in vivo can be tailored to match specific drug release 
requirements.  
As several of the approved microsphere drug products are coming off patent, generic 
companies are working to introduce generic equivalents. Microsphere drug products often 
contain a substantial amount of potent therapeutics, which makes them “high-risk” drug products 
since any unexpected change in bioavailability may result in severe side effects or toxicity. It has 
been reported that the critical physicochemical properties of compositionally equivalent 
polymeric microspheres (such as drug loading, particle size and porosity) are sensitive to minor 
changes in the manufacturing processes, which in turn may affect drug release characteristics and 
hence product performance. Accordingly, it is crucial to assure the performance and safety of 
such drug products. 
In vitro drug release tests must be performed to ensure their performance and safety, as 
well as assist in the product development and the regulatory approval processes.7, 8 However, 
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there is a lack of compendial in vitro release methods for microsphere dosage forms at present, 
and this has hampered the development and regulatory approval of both innovator and generic 
products. Hence, there is a need to develop in vitro release testing methods, that can be used to 
discriminate between in and out of specification batches. In vitro release testing methods are also 
necessary to support formulation, manufacturing site, scale-up and instrumentation changes. 
In addition, in vivo release tests of such drug products are time consuming, labor 
intensive and ethically undesirable. Hence, there is a need to develop bio-relevant in vitro release 
tests such that the in vitro release profiles correlate with the in vivo release profiles, allowing the 
development of an in vitro-in vivo correlation (IVIVC) or relationship (IVIVR). An IVIVC is 
intended to predict accurately and precisely the expected release characteristics of a product from 
the in vitro release profile. This may minimize the need to conduct in vivo release tests. 
Due to the complexity of the release profiles that typically occur from microsphere 
systems (bi or tri-phasic release curves), deconvolution of in vivo data and correlation with the in 
vitro release profiles is challenging. This is aggravated by the lack of understanding of the 
physicochemical properties of these formulations and the fact that most reported studies did not 
test Q1/Q2 equivalent formulations. As a result, most studies on in vitro-in vivo release from 
microspheres either report Level B IVIVCs, IVIVRs, or simple (non-mathematical) comparisons 
of the in vitro and in vivo release profiles.  
Our laboratory has recently demonstrated that the developed USP apparatus 4 based in 
vitro release testing method is able to discriminate small molecule microsphere formulations that 
are qualitatively (Q1) and quantitatively (Q2) equivalent in inactive ingredients, but have 
manufacturing differences9. Most importantly, this method has shown potential in predicting in 
vivo performance of the prepared Q1/Q2 equivalent microsphere formulations in a rabbit model. 
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1.2  Motivation 
In order to demonstrate whether IVIVCs/IVIVRs can be achieved for a variety of 
microsphere products with different physicochemical properties and release characteristics, we 
proposed to investigate Q1/Q2 equivalent microsphere products containing naltrexone. 
Naltrexone microspheres are commercially available (Vivitrol®). Naltrexone has different 
physicochemical properties compared to risperidone (such as solubility profile) and Vivitrol® has 
different release profiles compared to Risperdal Consta®. 
Moreover, compared with small molecule microsphere products, protein/peptide 
microsphere products are even more complex. Changes in the physicochemical characteristics of 
the protein/peptide microspheres as a result of manufacturing differences, as well as the 
instability of proteins/peptides during manufacturing, storage, and release in vivo may potentially 
result in inconsistent in vivo performance and immunogenicity. On the other side, therapeutic 
proteins and peptides are ideal for the treatment of numerous diseases as a result of their high 
selectivity and their ability to provide effective and potent action at low doses. Accordingly, it is 
crucial to understand the release mechanism of protein/peptide microspheres and how in vitro 
studies could be used to ensure product quality and predict in vivo bioavailability. Building on 
our previous research on small molecule Q1/Q2 equivalent microsphere formulations, it was then 
proposed to develop IVIVCs for Q1/Q2 equivalent protein/peptide microspheres with 
manufacturing differences. The therapeutic peptide, leuprolide acetate (LA) was chosen as the 
model peptide since it is in commercially available microsphere products (Lupron Depot®) that 
will shortly come off patent. 
1.3 Specific aims 
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The hypothesis of the proposed research is that, through an understanding of 
microsphere physicochemical properties and their relationship to manufacturing differences for a 
variety of therapeutics (i.e. small molecule and protein/peptide), an in vitro release testing 
method that will result in an in vitro-in vivo correlation (or in vitro-in vivo relationship) while 
also demonstrating discriminatory ability for out-of-specification formulations can be developed. 
To test this hypothesis the following research objectives are proposed: 
Specific Aim I: Preparation & characterization of Q1/Q2 equivalent naltrexone and leuprolide 
acetate microspheres with manufacturing differences.  
Specific Aim II: Development of discriminatory in vitro release testing method(s) for Q1/Q2 
equivalent naltrexone and leuprolide acetate microspheres. 
Specific Aim III: In vivo release testing and the development of an IVIVC/IVIVR for Q1/Q2 
equivalent naltrexone and leuprolide acetate microspheres. 
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Establishment of in vitro-in vivo correlations (IVIVCs) for parenteral polymeric 
microspheres has been very challenging, due to their complex multiphase release characteristics 
(which is affected by the nature of the drug) as well as the lack of compendial in vitro release 
testing methods. Previously, a Level A correlation has been established and validated for 
polymeric microspheres containing risperidone (a practically water insoluble small molecule 
drug). The objectives of the present study were: 1) to investigate whether a Level A IVIVC can 
be established for polymeric microspheres containing another small molecule drug with different 
solubility profiles compared to risperidone; and 2) to determine whether release characteristic 
differences (bi-phasic vs tri-phasic) between microspheres can affect the development and 
predictability of IVIVCs. Naltrexone was chosen as the model drug. Three compositionally 
equivalent formulations of naltrexone microspheres with different release characteristics were 
prepared using different manufacturing processes. The critical physicochemical properties (such 
as drug loading, particle size, porosity, and morphology) as well as the in vitro release 
characteristics of the prepared naltrexone microspheres and the reference-listed drug (Vivitrol®) 
were determined. The pharmacokinetics of the naltrexone microspheres were investigated using 
a rabbit model. The obtained pharmacokinetic profiles were deconvoluted using the Loo-
Riegelman method, and compared with the in vitro release profiles of the naltrexone 
microspheres obtained using USP apparatus 4. Level A IVIVCs were established and validated 
for predictability. The results demonstrated that the developed USP 4 method was capable of 
detecting manufacturing process related performance changes, and most importantly, predicting 
the in vivo performance of naltrexone microspheres in the investigated animal model. A critical 
difference between naltrexone and risperidone loaded microspheres is their respective bi-phasic 
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and tri-phasic release profiles with varying burst release and lag phase. These variations in 
release profiles affect the development of IVIVCs. Nevertheless, IVIVCs have been established 




















Owing to their advantages such as improved patient compliance and longer duration of action, 
extended release drug delivery systems have attracted great attention in the past several decades, 
resulting in the successful commercialization of various types of extended release drug products 
[1]. Parenteral polymeric microspheres, particularly poly(lactic-co-glycolic acid) (PLGA) and 
poly(lactic acid) (PLA) based microspheres have been one of the most effective non-oral 
extended release drug products on the market [2]. This is due to the fact that the PLGA/PLA-
based microsphere drug products are biodegradable and biocompatible with the ability to sustain 
the delivery of various therapeutics (e.g. small molecules and biologics) over long periods of 
time [3-6]. These microsphere drug products often contain a substantial amount of potent 
therapeutics, which makes them “high-risk” drug products since any unexpected change in 
bioavailability may result in severe side effects or toxicity [7]. Moreover, the critical 
physicochemical properties of polymeric microspheres (such as drug loading, particle size and 
porosity) are sensitive to minor changes in the manufacturing processes, which in turn may affect 
drug release characteristics and hence product performance [8]. Accordingly, it is crucial to 
assure the performance and safety of such drug products. 
In vitro drug release testing can provide extensive insight into the release rate as well as drug 
release mechanism(s) [9, 10]. Therefore, it is an important tool to not only ensure consistent 
product performance and safety, but also assist in product development. When a correlation 
between in vitro and in vivo drug release is established, the in vitro release method may 
potentially be used as a surrogate for bioequivalence studies that would otherwise be required for 
any scale-up and post-approval changes (SUPAC). The establishment of in vitro-in vivo 
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correlations (IVIVCs) minimizes the need for animal studies and clinical trials, and therefore 
reduces the cost and duration of generic microsphere drug product development. 
In vitro-in vivo correlation (IVIVC) is a predictive mathematical model describing the 
relationship between an in vitro property (e.g. rate or extent of drug release) of a dosage form 
and a relevant in vivo response (e.g. plasma drug concentration or amount of drug absorbed) 
[11]. The U.S. FDA has categorized four main levels of IVIVC: Levels A, B, C, and multiple 
level C. A Level A IVIVC represents a point-to-point correlation between the in vitro and in vivo 
input rates (e.g. the in vivo dissolution). It is considered the most informative, and is 
recommended by the U.S. FDA. A Level A IVIVC is also the only level of IVIVC that can be 
used to obtain a bio-waiver. In general, the U.S. FDA recommends the use of two or more 
formulations with different release characteristics in order to develop a reliable IVIVC.  
Unlike oral dosage forms, the establishment of an IVIVC for complex parenteral microsphere 
drug products has been very challenging. This is due to not only their complex characteristics 
(such as multiphase drug release profiles) but also the lack of a standard/compendial in vitro 
release testing method, which can mimic and predict their in vivo performance to the maximum 
extent possible [12-15]. Until now, literature reports on the establishment of IVIVCs for complex 
parenteral microsphere drug products have remained sparse. Most of the reported literature is on 
“proof-of-concept” research demonstrating the possibility of developing IVIVCs using one or 
two microsphere formulations with different release characteristics [16-22]. Recent research has 
demonstrated that a reliable Level A IVIVC can be developed for compositionally equivalent 
parenteral PLGA microspheres containing water insoluble small molecule therapeutics (such as 
risperidone) with manufacturing differences [8]. The drug loading as well as the burst release of 
microspheres containing water soluble therapeutics tends to be highly variable with minor 
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manufacturing changes. For example, the solvent exchange/evaporation rates during the 
microsphere solidification process are prone to vary, which in turn may alter drug loading and 
the drug release characteristics [23]. This is a very critical issue for the development of generic 
microsphere products. In addition, this makes it difficult to obtain two or more compositionally 
equivalent microsphere formulations with manufacturing differences for the development and 
validation of IVIVCs that would be useful for generic drug product manufacturers. Due to the 
solubility differences in aqueous and organic solvents, the release characteristics of such 
compounds from microspheres may significantly differ from that of water insoluble compounds 
(such as risperidone). For example, burst release is typically higher for water soluble compounds 
as a result of drug migration to the microsphere surfaces during preparation [23, 24]. As reported 
earlier, differences in the burst release affects the predictability of developed IVIVC [8]. Until 
now, a Level A IVIVC has not been reported for parenteral PLGA microspheres containing 
therapeutics that are soluble in water and have bi-phasic release characteristics.  
The objectives of the present study were to demonstrate whether a Level A IVIVC can be 
established using compositionally equivalent PLGA microspheres containing a small molecule 
with different solubility profiles compared to risperidone, and to investigate whether the 
differences in the release characteristics (bi-phasic vs tri-phasic) have an impact on the 
predictability of IVIVCs. Naltrexone (marketed in the microsphere form as Vivitrol®) was 
chosen as the model therapeutic. Three compositionally equivalent naltrexone PLGA 
microspheres with manufacturing differences were prepared. The in vitro release characteristics 
of the prepared naltrexone microsphere formulations and the reference listed drug (RLD) product 
were determined using a previously developed USP apparatus 4 method. The pharmacokinetic 
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profiles of the naltrexone microspheres were investigated using a rabbit model, and compared 
with the obtained in vitro release profiles to establish an IVIVC and investigate its predictability.  
2.2 Materials and Methods 
2.2.1. Materials  
PLGA (7525 DLG7E) was purchased from Evonik (Birmingham, AL). Anhydrous 
naltrexone base was purchased from Mallinckrodt Pharmaceuticals (St. Louis, MO). Poly (vinyl 
alcohol) (PVA, MW 30-70 kDa), trifluoroacetic acid (TFA), benzyl alcohol (BA) and the 
reference standard (i.e. naltrexone-D3) were purchased from Sigma-Aldrich (St. Louis, MO). 
Methylene chloride (DCM), ethyl acetate (EA), and dimethyl sulfoxide (DMSO, ACS grade) 
were purchased from Fisher Scientific (Pittsburgh, PA). LC-MS grade 0.1% v/v formic acid 
water and methanol were purchased from VWR (Radnor, PA). Milli-Q® water (Barnstead, 
Dubuque, IA) was used for all studies. All other chemicals were obtained commercially as 
analytical-grade reagents. 
2.2.2. Preparation of naltrexone microspheres 
PLGA (7525 DLG7E, Mw >100KD) with similar molecular weight as that used in the 
commercial product Vivitrol® was used to formulate compositionally equivalent naltrexone 
microspheres using different manufacturing processes. Briefly, 250 mg of PLGA was dissolved 
in organic solvent (i.e. ethyl acetate (16.7%, w/v) or methylene chloride (25%, w/v)). Naltrexone 
is poorly soluble in both methylene chloride and ethyl acetate and accordingly, a co-solvent 
(benzyl alcohol) was used to facilitate dissolution of naltrexone. The polymer solution was added 
to the naltrexone solution in benzyl alcohol (30%, w/v). The organic phase containing both the 
polymer and drug was then dispersed into a 1% (w/v) PVA solution (0.22 µm membrane 
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filtered), and an oil-in-water (o/w) emulsion was prepared by employing size reduction 
techniques such as homogenization (3,200 rpm for 60 sec) (IKA® Works, Inc.) and magnetic 
stirring (600 rpm for 15 min). The PVA solution was saturated with organic solvents (i.e. 1.8 and 
8.5 % (v/v) in the case of methylene chloride and ethyl acetate, respectively) in order to prevent 
abrupt precipitation of the polymer during emulsification. The resultant o/w emulsion was added 
to water (125 mL) and stirred at 220 rpm for 15 h to allow microsphere solidification. The 
organic solvents were then removed under vacuum at room temperature. The resultant 
microspheres retained on a 25 µm sieve were collected and washed using an aqueous ethanol 
solution (25% (v/v), <5°C). Lyophilization was used to dry the microspheres. 
2.2.3. Characterization of naltrexone microspheres 
2.2.3.1. High performance liquid chromatography (HPLC) analysis 
The quantification of naltrexone was conducted using a PerkinElmer HPLC system (series 
200) with a UV absorbance detector (PerkinElmer, Shelton, CT) set at 210 nm. The mobile phase 
was 10 mM phosphate buffer (pH 6.6)/methanol (35/65, v/v), and the flow rate was 1 mL/min. A 
Zorbax® C18 column (150 x 4.6 mm, 5 µm; Agilent technologies) was used as the stationary 
phase. The sample injection volume was 10 µL for drug loading and 50 µL for in vitro release 
testing sample analysis. The chromatographs were analyzed using a PeakSimple™ 
Chromatography System (SRI instruments, Torrance, CA).  
2.2.3.2. Drug loading 
The naltrexone microspheres (~4 mg) were weighed and transferred into 10 mL volumetric 
flasks. DMSO (2.5 mL) was added into the volumetric flasks and the samples were sonicated 
until all particles were dissolved. Methanol was used to dilute the sample. The solutions were 
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filtered (Millex® HV, 0.22 µm PVDF syringe filter) and the naltrexone concentrations were 
determined via the validated HPLC assay as described above. Drug loading was calculated as:  
Drug Loading (%) =  
weight of drug entrapped
weight of microspheres analyzed
 ×  100 
2.2.3.3. Particle size and size distribution  
Particle size and particle size distribution of the naltrexone microspheres were measured 
using an AccuSizer autodiluter particle sizing system (Nicomp, Santa Barbara, CA). Briefly, the 
microspheres were dispersed in a filtered 0.1% (w/v) PVA solution in water to ensure good 
dispersion, and then particle size analysis was conducted. 
2.2.3.4. Differential scanning calorimeter (DSC) analysis 
The glass transition temperatures (Tg) of the naltrexone microspheres were analyzed using a 
modulated temperature differential scanning calorimeter (MTDSC) (TA Instruments Q2000). 
Briefly, experiments were performed in hermetically sealed pans using a 2°C/min heating rate 
and a modulation amplitude of ± 0.82°C with an 80 s modulation period. The weight of each 
sample was ~ 5-6 mg. The Tg was determined as the glass transition midpoint in the reversing 
signal. 
2.2.3.5. Morphology  
The morphology of the commercial product Vivitrol® and the prepared naltrexone 
microspheres was analyzed using scanning electron microscopy (SEM). Briefly, dry 
microspheres were mounted on carbon taped aluminum stubs and sputter coated with gold under 




2.2.3.6. Porosity  
The porosity of the commercial product and the prepared naltrexone microspheres was 
determined using a Mercury Porosimeter (AutoPore IV 9500, Micromeritics). Briefly, 
approximately 200 mg of naltrexone microspheres were introduced into the porosimeter and 
tested at a mercury filling pressure of 0.53 psi. Total intrusion volume, total pore area as well as 
porosity (%) were recorded. 
Porosity (%) = (1 −  
Bulk density
Apparent (skeletal)density
) ×  100 
2.2.4. In vitro release studies 
In vitro release testing of the prepared naltrexone microspheres and the commercial product 
was conducted using a previously developed modified USP apparatus 4 method at 37°C [25]. 
Briefly, 10 mg of microspheres were mixed with glass beads (1 mm) and placed in the USP 
apparatus 4 dissolution cells. 50 mL of phosphate buffered saline (PBS) (10 mM, pH 7.4) 
containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide was circulated through the flow 
through cells at a flow rate of 8 mL/min at 37 °C. At pre-determined time intervals, one mL of 
samples were withdrawn and replenished with fresh media. The obtained samples were analyzed 
via HPLC. The release medium was replaced with fresh release medium every five days to avoid 
drug degradation. Media replacement during release testing was taken into account in the 
calculation of the fraction release. All drug release tests were conducted in triplicate and the 
results are reported as the mean % cumulative release ± SD. 
2.2.5. In vivo release studies 
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The in vivo release characteristics of the prepared naltrexone microspheres and the 
commercial product were investigated using a rabbit model. Briefly, male rabbits (New Zealand 
White) weighing approximately 3 to 4 kg were randomly assigned to each treatment group (n = 
6). The naltrexone microspheres were suspended in the diluent used for dispersion of the 
commercial product Vivitrol®, and injected into the rabbit hind leg thigh muscles at a dose of 
11.69 mg/kg. Blood samples were collected from the marginal ear veins at predefined time 
intervals. In addition, a pharmacokinetic study of the naltrexone solution in saline (dose: 0.11 
mg/kg, i.v.) was conducted (n = 6). The collected blood samples were centrifuged at 14,500 rpm 
for 5 min to separate out the plasma. The plasma was collected and stored at -80°C until analysis. 
The animal study protocol was reviewed and approved by the University of Connecticut's 
Institutional Animal Care and Use Committee (IACUC) prior to the beginning of the 
experiments. 
2.2.6. Plasma sample analysis 
Naltrexone was extracted from plasma samples using tert-butyl methyl ether by a liquid-
liquid extraction method. Naltrexone D-3 was used as the internal standard. Briefly, the internal 
standard solution (100 ng/mL, 20 µL) was added to 100 µL plasma samples. Samples were 
vortex-mixed for 5 min followed by addition of tert-butyl methyl ether (1 mL). Then the samples 
were vortex-mixed again for 15 min followed by centrifugation (4°C) at 14,500 rpm for 5 min. 
The supernatants were collected in polypropylene centrifugation tubes and the solvent was 
evaporated under nitrogen flow. The dry residues were then reconstituted with methanol (150 
μL) and injected into a LC-MS/MS system for sample analysis.  
The LC-MS/MS system consisted of an Agilent HP-1100 LC system and a TSQ Quantum 
Ultra Mass Spectrometer (Waters) with an electrospray ionization (ESI) ion source. 
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Chromatographic separations were carried out on a Kinetex HILIC column (50 x 2.1 mm, 2.6 
μm, 100 Å) through an isocratic mobile phase (0.1 % (v/v) formic acid in water/methanol (20/80, 
v/v)) at 30°C. The following MS detection parameters were used: 4000 V electrospray voltage, 
360°C capillary temperature, collision pressure 3.0, and 30 V collision energy. Detection of 
daughter ions was conducted in the positive-ion selected reaction monitoring mode with the 
following transitions in a single reaction monitoring (SRM) mode: m/z 342 (naltrexone) to m/z 
324.2 (dehydronaltrexone, daughter ion), and m/z 345.2 (naltrexone-D3) to m/z 327.2 
(dehydronaltrexone-D3, daughter ion). The injection volume was 15 μL. The data acquisition 
was ascertained by Xcalibur software. Calibration curves were established on each day when 
analysis was conducted, and showed good linearity with correlation coefficients > 0.99. The 
lowest limit of quantification (LLOQ) for naltrexone was 0.5 ng/mL and the mean recovery of 
plasma samples from low to high concentrations of naltrexone was more than 90%. The inter- 
and intra-day variations of the three different concentrations of naltrexone (0.5, 10, and 
20 ng/mL) were less than 15%. 
2.2.7. Pharmacokinetic analysis and the development of an IVIVC 
The development of IVIVC for the prepared naltrexone PLGA microspheres was performed 
following the same principles as detailed in the U.S. FDA guidance on development of IVIVC 
for extended release oral dosage forms [11]. Briefly, the in vivo plasma profiles of naltrexone 
PLGA microspheres were deconvoluted using the Loo-Riegelman method [14, 26]. Standard 
errors are not shown in the deconvoluted in vivo absorption profiles because the average plasma 










Cp, Ct, K10 and AUC are the drug concentration in the central compartment (plasma), 
apparent tissue compartment concentration, elimination rate constant and area under the plasma 
vs time curve, respectively. The distributive and elimination micro rate constants (k12, k21 and 
k10) that are necessary for calculating Ct, and the total fraction absorbed at time t, were calculated 
using WinNonlin® 6.4 (Pharsight, Certara corporation St.Louis, USA) based on the plasma 
concentrations of naltrexone after intravenous administration of the naltrexone solution. 
The development and validation of the IVIVC for the naltrexone microspheres were 
performed using WinNonlin® 6.4 (Pharsight, Certara corporation St. USA).  
2.2.8. Statistical data analysis 
Statistical analysis was performed to evaluate significant differences between different 
microsphere formulations using a paired student t-test. The level of significance was accepted 
at p < 0.05. 
2.3. Results and Discussion 
2.3.1.  Physicochemical properties of naltrexone microspheres 
It has been reported that the critical physicochemical properties (e.g. particle size, and 
porosity) of parenteral PLGA microspheres containing a water insoluble model compound 
(risperidone) are sensitive to minor changes in manufacturing processes (such as solvent systems 
and particle size reduction technique) [8]. In order to understand the effect of manufacturing 
processes on the physicochemical properties of parenteral PLGA naltrexone microspheres that 
were prepared using different manufacturing processes, three compositionally equivalent 
naltrexone microspheres were obtained: 1) Formulation 1_stirring (methylene chloride and 
benzyl alcohol solvent system); 2) Formulation 2_stirring (ethyl acetate and benzyl alcohol 
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solvent system); and 3) Formulation 3_homogenization (ethyl acetate and benzyl alcohol solvent 
system). 
The physicochemical properties of the prepared naltrexone microspheres with manufacturing 
differences and the RLD product are presented in Table 1. As shown in Table 1, all naltrexone 
microsphere formulations had similar drug loading (ca. 29%, w/w), and the RLD product had a 
slightly higher drug loading (33.5%). It was observed that maintaining high drug loading of the 
naltrexone microspheres was very challenging, since water soluble compounds can leak into the 
larger outer aqueous phase during the microsphere solidification process, resulting in low drug 
loading. Lower temperature (4°C) was used throughout the preparation process to minimize drug 
diffusion from the inner organic phase droplets into the aqueous phase. It has previously been 
reported that the polymer precipitation rate facilitates entrapment of most of the drug inside the 
core and hence, is critical to achieve high drug loading for hydrophilic drugs [23]. In the present 
study, solvent removal and consequent, polymer precipitation were controlled by continuously 
applying a vacuum at a constant pressure to achieve fast solvent evaporation and therefore fast 
microsphere solidification, to minimize drug loss into the aqueous phase during preparation. 
Particle size and particle size distribution of all three prepared naltrexone microsphere 
formulations and Vivitrol® are shown in Figure 1. Despite the fact that all the formulations were 
prepared using different manufacturing processes, the prepared naltrexone microspheres showed 
similar D50 values in terms of population distribution (ca. 50 μm), which were similar to that of 
Vivitrol®. Whereas, in the case of volume distribution, Formulation 3 showed a smaller D50 
value (ca. 68 μm) compared to Vivtrol® and the other two prepared formulations (ca. >100 μm) 
(p < 0.05). In addition, the span value of Formulation 3 was the lowest compared to that of 
Vivitrol® and Formulations 1 and 2, which indicates narrow size distribution. The microspheres 
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prepared using the stirring technique (i.e. Formulations 1 and 2) showed a large variation in the 
particle size distribution, while the microspheres prepared using the homogenization method (i.e. 
Formulation 3) showed comparatively smaller but uniform particle size. This can be explained 
by the fact that the homogenization process provided a stronger emulsification force, thus 
leading to a smaller particle size with a narrower size distribution compared to the stirring 
process. 
Table 1. Physicochemical properties of naltrexone microspheres investigated. 







Formulation 1 DCM&BA Magnetic Stirring 28.74±1.64 49.83 
Formulation 2 EA&BA Magnetic Stirring 29.7±1.11 58.32 
Formulation 3 EA&BA Homogenization 29.57±1.75 65.08 
Vivitrol® - - 33.50±1.43 50.21 
DCM: methylene chloride, EA: ethyl acetate, BA: benzyl alcohol 
 
Figure 1. Particle size and particle size distribution of Vivitrol® and the naltrexone microspheres 
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are expressed as mean ± SD (n = 3 batches) (* represents statistically different particle size 
compared to Vivitrol®). 
Differences in the manufacturing processes (such as different solvents, and rates of solvent 
diffusion and evaporation) have been reported to affect the inner structure and/or the porosity of 
PLGA microspheres [27, 28]. As shown in Figure 2, all the prepared naltrexone microspheres 
were polydispersed, and of a spherical shape with the presence of a few large pits on their 
surfaces. The presence of large pits on the microsphere surfaces may be due to shrinkage during 
the solvent evaporation process under vacuum. Furthermore, the naltrexone microspheres 
prepared using methylene chloride as the solvent (i.e. Formulation 1) had a lower percentage 
porosity (49.83%) compared to those microspheres prepared using ethyl acetate & benzyl 
alcohol as the solvent system (58.32% and 65.02% for Formulations 2 and 3, respectively) 
(Table 1). Since ethyl acetate is relatively more miscible with water compared to methylene 
chloride, water inclusion during microsphere solidification led to the formation of a porous core 
structure and hence higher porosity, which is consistent with our recent research on risperidone 
PLGA microspheres [29]. No significant differences were observed in the Tg of the naltrexone 
microspheres. 
 
Figure 2. SEM micrographs of the commercial product, Vivitrol® (A); Formulation 1 (B); 
Formulation 2 (C); and Formulation 3 (D). Symbol: The red arrows point to the pits of the 
microsphere surfaces. 
200 μm  200 μm 200 μm200 μm
A                                     B                                     C                                    D 
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Overall, it was observed that the critical quality attributes of the naltrexone microspheres 
(such as drug loading, particle size and porosity) are very sensitive to manufacturing differences 
such as the solvent system, the solvent removal rate, temperature and the particle size reduction 
technique. It was anticipated that the differences in these critical quality attributes of naltrexone 
microspheres may affect their in vitro and in vivo performance. 
2.3.2.  In vitro release characteristics of naltrexone microspheres 
One of challenges in developing an IVIVC for complex parenteral drug products (such as 
microspheres) is the lack of compendial in vitro release testing methods. Various methods have 
been used to investigate in vitro release profiles of parenteral polymeric microspheres, including 
sample-and-separate, dialysis and USP apparatus 4 methods [10, 30-32]. The 2004 AAPS-
EUFEPS workshop recommended a dissolution method using USP apparatus 4 for microspheres 
[12]. An effort has recently been made to develop a suitable in vitro release testing method for 
naltrexone microspheres [25]. However, due to instability issues associated with naltrexone, 
frequent media replacement was determined to be necessary during long-term release testing to 
avoid oxidative degradation. Based on recent research, a USP apparatus 4 method with excellent 
reproducibility was used to investigate the in vitro release characteristics of the naltrexone 
microspheres [25].  
As shown in Figure 3, the developed “real-time” USP apparatus 4 method was able to 
discriminate between the in vitro release profiles of all the prepared naltrexone microsphere 
formulations with manufacturing differences and also Vivitrol®. Unlike the previously reported 
risperidone microspheres [8], the naltrexone microspheres investigated showed bi-phasic release 
profiles, indicating naltrexone release from these microspheres may be governed by a 
combination of drug diffusion and polymer degradation. Drugs that are soluble in water can 
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more easily diffuse into the release media compared to water insoluble compounds such as 
risperidone. Hence, there may be continuous release of drug from microsphere pores even in the 
absence of polymer degradation. Consequently, such drugs encapsulated in PLGA microspheres 
may have bi-phasic release profiles with no or very short lag phase.  
Formulations 1 and 2 reached more than 90% release at around day 40 and day 30, 
respectively, and had initial lag phases of approximately five days compared to Vivitrol® and 
Formulation 3, which did not have a lag phase (Figure 3). The naltrexone microspheres prepared 
using the homogenization method (Formulation 3) which had a small and uniform particle size 
distribution as well as a highly porous structure, exhibited a much faster release rate and 
plateaued at around day 20. This can be compared to Formulations 1 and 2, which had larger 
particle size and longer release duration. Small microspheres have a shorter diffusion distance 
and the highly porous structure of Formulation 3 also facilitates diffusion. In addition, the 
increased water penetration leads to faster polymer degradation, which also facilitates drug 
release. Among the three prepared naltrexone microsphere formulations, Formulation 2 had an 
intermediate release rate due to its larger particle size compared to Formulation 3, and its higher 
porosity compared to Formulation 1. Formulation 1 showed the slowest release profile. This is 
considered to be a result of the low porosity and large particle size of Formulation 1 (Table 1). 
Interestingly, all the prepared naltrexone microsphere formulations showed low burst release. 
This was achieved by the use of low temperature (4°C) and high vacuum throughout the 
microsphere preparation process, which increases the polymer precipitation rate causing the drug 
to be entrapped within the microsphere matrix, resulting in a low burst release percentage. 
Furthermore, the in vitro release profile of the RLD product was initially similar to Formulation 
3 with no lag phase, however the release rate and duration were closest to Formulation 1. The 
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RLD product may be prepared via a different manufacturing process and/or with a different 
PLGA polymer. These results reaffirm, using another small molecule model compound, that the 
in vitro release characteristics of PLGA microspheres are very sensitive to changes in the 
manufacturing processes.   
 
Figure 3. In vitro release profiles of compositionally equivalent naltrexone microsphere 
formulations (with manufacturing differences) and Vivitrol®. The developed USP apparatus 4 
method was used at 37°C in 10 mM PBS (pH 7.4) containing 0.02% (w/v) Tween 20 and 0.02% 
(w/v) sodium azide (n = 3). The release media was replaced every five days.  
2.3.3.  In vivo release characteristics of naltrexone microspheres 
The pharmacokinetic profiles of the naltrexone solution following single intravenous 
administration (i.v.), and of the naltrexone microspheres following intramuscular administration 
(i.m.) in rabbits are shown in Figures 4A and 4B, respectively. The in vivo profiles of all 
naltrexone microspheres (Figure 4B) were determined to have good correlation with their 
respective in vitro release profiles (Figure 3). Formulation 1 showed a slower absorption peak 
(Tmax, Day 5) with the longest absorption/release duration (30 days) compared to the other 














































Day 4) as well as an overall intermediate absorption/release duration (22 days), while 
Formulation 3 had the earliest absorption peak (Tmax, Day 2) with the shortest absorption/release 
duration (15 days). These results are in line with the in vitro release profiles and with the 
differences in the porosity and mean particle size among the three formulations, as discussed 
above. 
 
Figure 4. Mean plasma concentration-time profiles of naltrexone in rabbits following: (A) 
intravenous administration of the naltrexone solution at a single dose of 0.11 mg/kg; and (B) 
intramuscular administration of naltrexone PLGA microspheres at a single dose of 11.69 mg/kg 
(mean ± SD, n = 6). 
Key pharmacokinetic parameters of the naltrexone solution following i.v. administration 
were analyzed using WinNonlin® 6.4 (Pharsight, Certara corporation, St. Louis, USA) and are 
shown in Table 2. These pharmacokinetic parameters were used to deconvolute the 
pharmacokinetic profiles ((i.m.) of the naltrexone microspheres investigated using the Loo-
Riegelman method [26]. As shown in Figure 5, the deconvoluted in vivo profiles of the Vivitrol® 
and the prepared naltrexone microspheres followed the same rank order as their in vitro release 
profiles: Formulation 3 > Formulation 2, Vivitrol® > Formulation 1 (Figure 3). It is also 
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vivo and this is consistent with their in vitro release profiles, whereas Formulations 1 and 2, 
which showed a lag phase in their in vitro release profiles also showed evidence of a change in 
the release rate in vivo around day four. 
 The deconvoluted in vivo release profiles appeared to be faster compared to their respective 
in vitro release profiles (Figure 3). As reported previously, this might be due to enhanced 
polymer degradation as a result of local acidic pH [18, 20] and the presence of other biological 
components (such as enzymes [33]) accelerating polymer degradation and thereby drug release 
in vivo. Moreover, the in vivo drug release profile of Vivitrol® in rabbits appeared to have a 
slightly shorter duration with a faster release rate compared to the clinical data reported in 
literature [34]. This is consistent with our recent research on risperidone microspheres, where the 
rabbit pharmacokinetic data were significantly faster than the clinical data [8]. It is suspected that 
the differences in the local environment (such as interstitial fluid volume, blood flow and the 
presence of other biological components) between the rabbit hind leg thigh muscle and human 
gluteal muscle as well as differences in drug metabolism may be responsible for the interspecies 
differences in the pharmacokinetics of both naltrexone and risperidone and their respective 
microsphere formulations [35].  
Table 2. Pharmacokinetic parameters of the naltrexone solution following intravenous 
administration (n=6). 









Figure 5. In vivo fraction absorbed/released profiles (i.m.) of naltrexone microspheres prepared 
with manufacturing differences and Vivitrol® (deconvoluted using the Loo-Riegelman method 
from the data presented in Figure 4). 
It was demonstrated that despite all the prepared naltrexone microspheres being 
compositionally equivalent, they had different in vitro and in vivo drug release characteristics 
due to the differences in their physicochemical characteristics resulted from different 
manufacturing processes. 
2.3.4. IVIVC 
The “Guidance for industry, extended release oral dosage forms” recommends the use of a 
minimum of two, preferably three or more formulations with different release rates to develop an 
IVIVC if the in vitro release of the formulations is dependent on the release testing 
conditions [11]. It has been previously demonstrated that naltrexone release from the prepared 
microsphere formulations was dependent on the release testing conditions (such as pH, medium 
additives and temperature) [25]. Accordingly, all three prepared naltrexone microsphere 
formulations with different in vitro and in vivo drug release characteristics (Figures 3 and 4B) 










































combination of two formulations out of the three prepared naltrexone microsphere formulations 
was plotted against the time-shifted fraction released in vitro at the respective time points to 
determine the correlation if any. The time-shifting factor (5.2) was kept the same for all 
naltrexone microspheres investigated. As shown in Figure 6 (A, C and E), an affirmative IVIVC 
(i.e. a Level A, point-to-point correlation, as per U.S. FDA guidance) between the fractions 
released in vitro and fractions released/absorbed in vivo was observed for all combinations 
(correlation coefficients greater than 0.94). All the developed IVIVCs were comparable as 
manifested by similar slopes and intercepts.  
The IVIVC equation obtained using two internal formulations was used to predict the in vivo 
performance of the third external formulation from its “real-time” in vitro release profile. The 
predicted in vivo profile of the third external formulation was compared with its deconvoluted in 
vivo profiles obtained in rabbits. As shown in Figure 6 (B, D and F), the predicted in vivo 
profiles of Formulations 1 and 2 were similar to the observed in vivo profiles with no significant 
difference. However, that of Formulation 3 did show differences, particularly within the first 8 
days. This may be due to the dissimilarity in the drug release profile of Formulation 3 compared 
to Formulations 1 and 2, in that Formulation 3 does not exhibit a lag phase.  
  
y = 0.9995x + 0.0148 
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 Figure 6. Level A IVIVC developed for naltrexone microspheres using the Loo-Reigelman 
method (time shifting factor: 5.2). (A) IVIVC_1 (developed using Formulations 1 and 2). (B) 
Experimental and predicted in vivo release profiles of Formulation 3. (C) IVIVC_2 (developed 
using Formulations 2 and 3). (D) Experimental and predicted in vivo release profiles of 
Formulation 1. (E) IVIVC_3 (developed using Formulations 3 and 1). (F) Experimental and 
predicted in vivo release profiles of Formulation 2. 
The in vivo release profile of the commercial product Vivitrol® was also predicted from its 
“real-time” in vitro release profile using all three developed IVIVCs, and compared with its 
observed in vivo profile (deconvoluted) obtained in rabbits. As shown in Figure 7, all three 
predicted in vivo release profiles were similar to the observed in vivo profiles, irrespective of 
which developed IVIVC was used. However, during the initial release period (of approximately 
y = 0.9686x + 0.0206 
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four to five days), the predicted release profile of Vivitrol® was slightly higher than that 
observed. It would appear that microsphere formulations with and without a lag phase are not 
ideal predictors of one another. A similar observation has been reported for compositionally 
equivalent risperidone microsphere formulations with manufacturing differences, where 
formulations with high burst release were not ideal predictors for formulations with low burst 
release. However, for the compositionally equivalent risperidone microspheres, the developed 
IVIVCs showed acceptable predictability in terms of % prediction error of AUC0-last and Cmax as 
per U. S. FDA guidance irrespective of differences in burst release. 
 
Figure 7. Experimental and predicted (time shifting factor: 5.2) in vivo release profiles of 
Vivitrol® using the developed IVIVCs. IVIVC_1 developed using Formulations 1 and 2. 
IVIVC_2 developed using Formulations 2 and 3. IVIVC_3 developed using Formulations 3 and 
1. 
The internal validation of the developed IVIVC model was accomplished by convolving the 
in vitro/in vivo release data of Formulations 1 and 3, since Formulations 1 and 3 had the slowest 
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AUC of these two formulations. The PE% values of the Cmax and AUC of Formulation 1 were -
1.68 and -12.16, respectively. The PE% values of the Cmax and AUC of Formulation 3 were -
22.24 and -1.92, respectively. The average absolute %PE value of Cmax and AUC were 11.96 
and 7.04, respectively. As per the U.S. FDA guidance [11], the predictability can be acceptable 
when the average absolute %PE values are of 10% or less and the %PE value for each 
formulation should not exceed 15%. In the present study, the average absolute internal %PE for 
the AUC (7.04%) was within the recommended range of 10% or less. However, the average 
absolute internal %PE for Cmax (11.96%) was slightly more than 10%, suggesting the internal 
predictability of the developed IVIVC for Cmax was inconclusive.  The FDA guidance states that 
if the criteria for internal validation are not met, the external predictability should be evaluated as 
the final determination of the IVIVC model.  Accordingly, the evaluation of external 
predictability of the IVIVC was performed. It can be seen in Table 3 that the external %PE for 
Cmax and AUC0-last were 3.38% and 10.13%, respectively, which is in accordance with the 
recommended external predictability evaluation (%PE of 10% or less). These results indicate that 
the developed IVIVC has good external predictability, thus could be used as a surrogate for 
bioequivlance in rabbits. Furthermore, the predictability of the developed IVIVC for Vivtrol® 
was also investigated. Both %PEs for Cmax (-9.27%) and AUC0-last (9.53%) were below 10%. 
These results confirmed that the developed IVIVC for naltrexone microspheres can be used to 
predict not only the prepared compositionally equivalent formulations with manufacturing 
differences but also a microsphere formulation with relatively similar composition and drug 
loading.  




 Cmax (μg/L) AUC0-last (μg/L* day) 
Internal validation Obs. Pred. %PE Obs. Pred. %PE 
Formulation1 7.98 7.84 -1.68 80.82 70.99 -12.16 
Formulation 3 18.78 14.61 -22.24 72.17 70.79 -1.92 
Average Internal   11.96   7.04 
External Validation       
Formulation 2 7.49 7.74 3.38 62.78 69.14 10.13 
Prediction       
Vivitrol® 7.54 6.84 -9.27 74.60 81.70 9.53 
 
2.4. Conclusions 
The present manuscript describes for the first time that a Level A IVIVC based on a 
compendial dissolution apparatus (USP apparatus 4) can be developed for compositionally 
equivalent PLGA microspheres containing a therapeutic that is water soluble (i.e. naltrexone), 
and for PLGA microspheres with bi-phasic release characteristics. The critical quality attributes 
of the naltrexone microspheres (such as drug loading, particle size, and porosity) were very 
sensitive to manufacturing differences such as solvent system, solvent removal rate, and 
temperature as well as the particle size reduction technique. It was shown that solvent removal, 
drug diffusion and polymer precipitation during microsphere solidification must be closely 
controlled in order to maintain consistently high drug loading for microspheres containing 
hydrophilic therapeutics. The developed USP apparatus 4 method was able to detect in vitro 
performance changes resulting from manufacturing processes differences and most importantly, 
predict in vivo performance of the naltrexone microspheres. Due to the instability issues 
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associated with naltrexone, frequent medium replacement was implemented during long-term 
release testing to prevent oxidative degradation of naltrexone. Together with our previous 
research on developing a Level A IVIVC for polymeric microspheres containing a water 
insoluble therapeutic (e.g. risperidone) with tri-phasic release characteristics, it can be concluded 
that Level A IVIVCs can be developed for parenteral microsphere drug products using USP 
apparatus 4 in a rabbit model. However, considering the interspecies differences between 
animals and humans, further investigation is necessary to determine whether an IVIVC can be 
developed using clinical data. In addition, it would appear that care should be taken in 
developing and applying IVIVCs to formulations with significant differences in burst release and 
lag phases.  
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The objective of the present study was to develop a discriminatory and reproducible accelerated release 
testing method for naltrexone loaded parenteral polymeric microspheres. The commercially available 
naltrexone microsphere product (Vivitrol®) was used as the testing formulation in the in vitro release 
method development, and both sample-and-separate and USP apparatus 4 methods were investigated. 
Following an in vitro drug stability study, frequent media replacement and addition of anti-oxidant in the 
release medium were used to prevent degradation of naltrexone during release testing at “real-time” 
(37°C) and “accelerated” (45°C), respectively. The USP apparatus 4 method was more reproducible than 
the sample-and-separate method. In addition, the accelerated release profile obtained using USP apparatus 
4 had a shortened release duration (within seven days), and good correlation with the “real-time” release 
profile.  Lastly, the discriminatory ability of the developed accelerated release method was assessed using 
compositionally equivalent naltrexone microspheres with different release characteristics. The developed 
accelerated USP apparatus 4 release method was able to detect differences in the release characteristics of 
the prepared naltrexone microspheres. Moreover, a linear correlation was observed between the “real-
time” and accelerated release profiles of all the formulations investigated, suggesting that the release 
mechanism(s) remain the same under both conditions. These results indicate that the developed 
accelerated USP apparatus 4 method has the potential to be an appropriate quality control tool for long-











Biodegradable polymeric microsphere system based parenteral controlled release drug products have been 
widely used for long-term controlled delivery of small molecule therapeutics as well as biologics such as 
peptides and proteins owing to their various clinical advantages such as low dosing frequency and hence 
improved patient compliance, as well as their ability to maintain effective therapeutic concentrations over 
extended periods of time, thus enhancing product safety and efficacy [1, 2]. As the improved therapy of 
these controlled release drug products is rooted in the optimum drug concentration/time profiles at the site 
of action in the body, therefore, it is essential to understand drug release characteristics of these types of 
drug products to ensure product performance and safety. 
“Real-time” in vitro release testing is typically conducted to characterize drug release characteristics 
under physiological conditions [3, 4]. However, “real-time” in vitro release testing of controlled release 
formulations often runs over a long period of time ranging from weeks to months, or even years [5-8], 
which if applied to batch release testing would result in reduced effective product shelf-life. 
Consequently, there is a need to develop fast and reliable quality control tool(s) to assure product 
performance as well as batch-to-batch reproducibility for consistent pharmacological effect. An 
accelerated in vitro release testing method, which increases drug release rate and hence reduces the testing 
duration, can aid in fast production batch release as well as speed up product development.  
Various conditions such as high temperature [9], extreme pH [10, 11], organic solvent as well as 
addition of surfactant [12], have been used to accelerate drug release from PLGA microspheres [13]. All 
these approaches speed up the drug release rate via different mechanisms such as increased molecular 
mobility of the drug as well as the polymer chains and increased water/media penetration, all of which 
lead to fast drug diffusion and enhanced polymer degradation rate. It is known that drug release from 
polymeric microspheres is mainly controlled by a combination of drug diffusion and polymer erosion 
[14]. Selection of an appropriate accelerated approach depends on various factors such as the polymer 
glass transition temperature [10, 15, 16], and the drug stability under various stress testing conditions 
[17]. Ideally, accelerated in vitro release profiles should have 1:1 linear correlation with “real-time” 
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release profiles after time scaling/shifting [14]. A 1:1 linear correlation shows that the exposure of 
polymeric microspheres to such stress conditions does not alter the underlying drug release mechanism(s) 
[12]. However, the use of extreme conditions to accelerate drug release may change the mechanism(s) of 
drug release. Nevertheless, the accelerated drug release profiles should follow at least the same rank order 
as the “real-time” release profiles [18]. Most importantly, the accelerated in vitro release testing method 
should be able to differentiate any significant variation in drug release characteristics of formulations in 
order to be used as a quality control tool, i.e. the method should show good discriminatory ability [19]. 
This is because minor manufacturing process changes may result in alteration of the release 
characteristics [20].  
Owing to the complexity of these controlled release drug products, currently there is no compendial 
method available for parenteral polymeric microspheres. Various in vitro release testing methods have 
been used to investigate “real-time” and accelerated in vitro release characteristics of parenteral 
polymeric microspheres, including dialysis, sample-and-separate and USP apparatus 4 methods [9, 21-
23]. The sample-and-separate method is simple, and provides reasonably accurate assessment of in vitro 
drug release, which makes it useful during the initial stages of product development. On the other hand, 
the USP apparatus 4 (continuous flow through) method utilizes a compendial apparatus with well-defined 
geometry and hydrodynamic conditions and hence, offers various advantages such as better 
reproducibility [24]. The U.S. FDA has recommended that a dissolution method using USP apparatus 4, 
and, if applicable, USP apparatus 2 (Paddle) or any other appropriate method, should be developed for 
comparative in vitro release evaluation of such drug products. Accordingly, both sample-and-separate and 
USP apparatus 4 methods were investigated in the present study. The aim of the present work was to 
develop a reproducible and discriminatory accelerated in vitro release testing method for compositionally 
equivalent polymeric microspheres with manufacturing differences. Naltrexone (the active 
pharmaceutical ingredient in the commercial microsphere product Vivitrol®) was chosen as a small 
molecule model therapeutic. Compositionally equivalent polymeric microspheres were prepared using 
different manufacturing processes. Both sample-and-separate and USP apparatus 4 methods were 
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investigated. Furthermore, the reproducibility and discriminatory ability of the developed accelerated 
release method were assessed. 
3.2.Materials and Methods 
3.2.1. Materials  
PLGA (7525 DLG7E, MW>100 kDa) was purchased from Evonik (Birmingham, AL). Anhydrous 
naltrexone base was purchased from Mallinckrodt Pharmaceuticals (St. Louis, MO). Poly (vinyl alcohol) 
(PVA, MW 30-70 kDa), trifluoroacetic acid (TFA), and benzyl alcohol (BA) were purchased from 
Sigma-Aldrich (St. Louis, MO). Methylene chloride (DCM), ethyl acetate (EA), and dimethyl sulfoxide 
(DMSO, ACS grade) were purchased from Fisher Scientific (Pittsburgh, PA). Milli-Q® water (Barnstead, 
Dubuque, IA) was used for all studies. All other chemicals were obtained commercially as analytical-
grade reagents. 
3.2.2. Methods 
3.2.2.1.Preparation of naltrexone microspheres 
PLGA with similar molecular weight as that in the commercial product Vivitrol® was used to formulate 
naltrexone microspheres using an oil-in-water (o/w) emulsion solvent extraction/evaporation technique. 
Briefly, 250 mg of PLGA (7525 DLG7E) was dissolved in organic solvent (i.e. ethyl acetate or methylene 
chloride). Naltrexone was dissolved in benzyl alcohol (30%, w/v) and added to the polymer solution. The 
organic phase was added to a 1% (w/v) PVA solution pre-saturated with organic solvent used (to prevent 
abrupt precipitation of the polymer during preparation), and an o/w emulsion was then prepared by 
employing droplet size reduction techniques such as homogenization or magnetic stirring. The resultant 
o/w emulsion was added to the aqueous phase and stirred at 220 rpm for 15 h to allow microsphere 
solidification and solvent removal under vacuum at room temperature. Microspheres were then removed 
from vacuum and sieved using two sieves, a 212 μm sieve on the top and 25 μm sieve on the bottom. The 
microspheres retained on the 25 μm sieve were collected, washed using an aqueous ethanol solution (25% 
(v/v), <5°C), and lyophilized.  
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3.2.2.2.Characterization of physicochemical parameters of naltrexone microspheres 
3.2.2.2.1. High performance liquid chromatography (HPLC) analysis 
The quantification of naltrexone was conducted using a PerkinElmer HPLC system (series 200) with a 
UV absorbance detector (PerkinElmer, Shelton, CT) set at 210 nm. The mobile phase was phosphate 
buffer (10 mM, pH 6.6)/methanol (35/65, v/v) and the flow rate was 1 mL/min. A Zorbax® C18 column 
(150 x 4.6 mm, 5 μm; Agilent technologies) was used as the stationary phase. The sample injection 
volume was 10 μL for drug loading determination and 50 μL for in vitro release testing sample analysis. 
The chromatographs were analyzed using a PeakSimple™ Chromatography System (SRI instruments, 
Torrance, CA).  
3.2.2.2.2. Drug loading 
The naltrexone microspheres (~4 mg) were weighed and transferred into 5 mL volumetric flasks. DMSO 
(2.5 mL) was added into the volumetric flasks and the samples were sonicated until all particles were 
dissolved. Methanol was used to dilute the sample. The solution was filtered (Millex® HV, 0.22 μm 
PVDF syringe filter) and the naltrexone concentration was determined with a validated HPLC assay. 
Drug loading was calculated as:  
 
% 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑒𝑛𝑡𝑟𝑎𝑝𝑝𝑒𝑑 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠 𝑎𝑛𝑎𝑙𝑦𝑧𝑒𝑑
 𝑥 100 
3.2.2.2.3. Particle size analysis  
Particle size and particle size distribution of the naltrexone microspheres were measured using an 
AccuSizer autodiluter, single particle optical sizing system (Nicomp, Santa Barbara, CA). Briefly, 
microspheres were dispersed in a filtered 0.1% (w/v) PVA solution in water to ensure good dispersion for 
the particle size analysis. 
3.2.2.2.4. Differential scanning calorimeter (DSC) analysis 
The glass transition temperatures (Tg) of the naltrexone microspheres were analyzed using a modulated 
temperature differential scanning calorimeter (MTDSC) (TA Instruments Q2000). Briefly, experiments 
 
 45 
were performed in hermetically sealed pans using a 2°C/min heating rate and a modulation amplitude of 
± 0.82°C with an 80 s modulation period. The weight of each sample was ~ 5-6 mg. The Tg was 
determined as the glass transition midpoint in the reversing signal. The crystallinity of naltrexone was 
also investigated. 
3.2.2.2.5. Porosity  
Porosity of the prepared naltrexone microspheres was determined using a Mercury Porosimeter (AutoPore 
IV 9500, Micromeritics). Briefly, approximately 200 mg of the naltrexone microspheres were introduced 
into the porosimeter and tested at a mercury filling pressure of 0.53 psi. Total intrusion volume, total pore 
area as well as porosity (%) were recorded.  
 
% 𝑝𝑜𝑟𝑜𝑠𝑖𝑡𝑦 =  1 −
𝑏𝑢𝑙𝑘 𝑑𝑒𝑛𝑠𝑖𝑡𝑦
𝑎𝑝𝑝𝑎𝑟𝑒𝑛𝑡 (𝑠𝑘𝑒𝑙𝑒𝑡𝑎𝑙)𝑑𝑒𝑛𝑠𝑖𝑡𝑦
 𝑥 100 
3.2.2.3.In vitro drug degradation study  
An exhaustive study was performed in order to understand whether naltrexone was stable under different 
in vitro release testing conditions such as phosphate buffered saline with different pH (i.e. 4.5, 6.0, 7.4, 
and 9.0), and temperature (i.e. 37°C and 45°C). 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide 
were added to the testing media since they are included in the FDA recommended dissolution medium 
[25]. In addition, the effect of antioxidant (i.e. sodium ascorbate) on the prevention of drug degradation 
was investigated. 
3.2.2.4.“Real-time” in vitro release study 
Vivitrol® was used as the testing microsphere drug product to develop suitable in vitro release testing 
method(s) for naltrexone microspheres. Both sample-and-separate and USP apparatus 4 methods were 
investigated. In the case of the sample-and-separate method, 10 mg of microspheres were suspended in 50 
mL of phosphate buffered saline (PBS, 10 mM, pH 7.4) with 0.02% (v/v) Tween 20 and 0.02% (w/v) 
sodium azide and incubated in a water shaker bath at 100 rpm at 37°C. At pre-determined time intervals, 
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one mL of release samples were withdrawn and centrifuged at 3,000 rpm for 3 min. Supernatants 
(0.9 mL) were filtered through 0.22 μm filters and analyzed via HPLC. Fresh medium (0.9 mL) was 
mixed with the pellets (if any) and transferred back to the testing vessels. In the case of the USP apparatus 
4 method, 10 mg of microspheres were mixed with glass beads (1 mm) and placed in the USP apparatus 4 
dissolution cell. The method of mixing the microspheres and the glass beads was as previously reported 
[14]. 50 mL of PBS (10 mM, pH 7.4) with 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide was 
circulated through the flow through cells at a flow rate of 8 mL/min at 37°C. At pre-determined time 
intervals, 1 mL of samples were withdrawn and replenished with fresh media. The obtained samples were 
analyzed via HPLC. The release medium was replaced with fresh release media every five days to avoid 
drug degradation during testing. Media replacement during the release testing was taken into account in 
the calculation of the fraction released. All drug release tests were conducted in triplicate, and the results 
were reported as the mean % cumulative release±SD. 
3.2.2.5.Accelerated in vitro release study 
Extreme release testing conditions (such as high temperature and pH) were investigated in order to 
develop a suitable accelerated in vitro release testing method. Due to the instability of naltrexone under 
extreme pH conditions, an elevated temperature accelerated in vitro release method at 45°C was 
developed. Similar in vitro release testing procedures as described in 2.2.4. were used. Sodium ascorbate 
(SA) (0.0625%, w/v) was added to the release medium to avoid media replacement during accelerated in 
vitro release testing.  
3.2.2.6.Statistical data analysis 
Statistical analysis was performed to evaluate significant differences between different microsphere 
formulation characteristics using a paired student t-test. The level of significance was accepted 
at p < 0.05. 
3.3.Results and Discussion 
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3.3.1. In vitro drug degradation study 
It has been reported in the literature that naltrexone base is prone to pH and temperature 
dependent oxidative degradation [26]. In order to select suitable media for in vitro release testing 
of naltrexone microspheres, the stability of naltrexone under different release testing conditions 
(such as different pH, and temperature) was investigated. As shown in Figure 1, naltrexone was 
relatively stable (< 5% degraded over 30 days) at low pH (i.e. pH 4.5 and pH 6.0) at 37°C. 
Whereas, naltrexone degradation was dramatically increased at higher pH (i.e. pH 7.4 and pH 
9.0) at 37°C, particularly at pH 9.0 (~25% degraded by day 5). At pH 7.4, naltrexone appeared to 
be relatively stable since at day 5 only ~ 3% degraded at 37°C. In addition, naltrexone 
degradation was accelerated at pH 7.4 under elevated temperature (45°C) resulting in more than 
10% degradation at day 5 (Figure 2). The degradation product was collected and analyzed using 
LC-MS/MS. A peak with an m/z value of 374.14 was observed (data not shown), suggesting the 
presence of an N-oxide product of naltrexone (C20H24NO6) (as shown in Figure 3). The basic 
drug naltrexone deprotonates under alkaline conditions and therefore, the drug may be more 
susceptible to electron loss and hence oxidative degradation. It was observed that the addition of 
an antioxidant (0.0625% (w/v) sodium ascorbate) in the medium (PBS, pH 7.4) containing 
0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide, can protect naltrexone against oxidation 
up to 10 days at 37°C (~4% degraded by day 10) (data not shown). This suggested that 0.0625% 
(w/v) sodium ascorbate may be used to prevent naltrexone degradation during elevated 
temperature release testing at 45°C, whereas media replacement may be necessary for “real-
time” release testing. Accordingly, “real-time” in vitro release testing of naltrexone microspheres 
at 37°C was performed via frequent media replacement (every five days) to avoid oxidative drug 




Figure 1. Effect of pH on the stability of naltrexone at 37°C (n=3). All the media contain 0.02% 
(v/v) Tween 20 and 0.02% (w/v) sodium azide. 
 
Figure 2. Effect of temperature on the stability of naltrexone in PBS buffer (10 mM, pH 7.4) 
containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide (n=3). (A) 37°C and (B) 45°C.  
3.3.2. “Real-time” in vitro release testing of naltrexone microspheres 
The commercially available naltrexone microsphere product Vivitrol® was used as the 
testing formulation for the development of reproducible and discriminatory in vitro 
release testing method(s). Since there is a lack of compendial in vitro release testing 
methods available for parenteral microsphere drug products, the two most commonly 
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Figure 3. Possible oxidative degradation pathway of naltrexone under the in vitro release testing 
conditions investigated.  
investigated. As shown in Figure 4, sustained naltrexone release from Vivitrol® with a very low 
initial burst release (ca. 0.5%) was observed, indicating that most of the drug was possibly 
entrapped inside the microsphere core during preparation. It was observed that more than 90% 
naltrexone was released from Vivitrol® by day 35 at 37°C, which is consistent with naltrexone 
release from Vivitrol® in vivo (over a period of 40 days) [27]. Since the release medium was 
replaced every five days, no major degradation peak(s) in the HPLC chromatograms were 
observed throughout testing, confirming that frequent media replacement can be implemented to 
avoid naltrexone degradation in the release media (10 mM PBS, pH 7.4) containing 0.02% (v/v) 
Tween 20 and 0.02% (w/v) sodium azide. Reproducibility of the “real-time” USP apparatus 4 
method was also investigated. It can be seen from Figure 5 that the in vitro release profiles of 
Vivitrol® (different batches, A and B) obtained at different testing dates overlapped, indicating 




Molecular weight: 341 
Molecular formula: C20H23NO4  
Degradation Product  
Molecular weight: 374 




Figure 4. In vitro release profile of Vivitrol® in 10 mM PBS (pH 7.4) containing 0.02% (v/v) 
Tween 20 and 0.02% (w/v) sodium azide at 37ºC obtained using the USP apparatus 4 method 
(n=3). The dissolution media was replaced every 5 days. 
 
Figure 5. In vitro release profiles of different batches of Vivitrol® in 10 mM PBS (pH 7.4) 
containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide obtained using the USP 
apparatus 4 method (n=3) at 37ºC. The dissolution medium was replaced every 5 days. 
In vitro release testing of the two batches of Vivitrol® (Batch A and B) was also performed 
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was observed by day 27. However, the in vitro release profiles of the two batches of Vivitrol® 
differed from one another when the sample-and-separate method was used. Since sample 
separation as well as media replacement via centrifugation was performed during release testing, 
variable amounts of sample loss during sample collection as well as media replacement might 
have occurred, thus resulting in irreproducible results. Although release media containing 0.02% 
Tween 20 was used to facilitate microsphere wetting as well as to minimize aggregation, 
microsphere aggregation was observed during testing. Compared to the sample-and-separate 
method, no sample separation and hence microsphere loss occurred when the USP apparatus 4 
method was used. In addition, the addition of glass beads in the USP apparatus 4 dissolution cells 
minimizes microsphere aggregation, as well as facilitates laminar flow of the release medium 
throughout the dissolution cells. Lastly, the USP apparatus 4 method is based on compendial 
dissolution apparatus with well-defined geometry and hydrodynamic conditions, which can 
facilitate inter-laboratory comparisons. Taken together, the USP apparatus 4 method appears to 
be a suitable in vitro release testing method for naltrexone microspheres.  
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containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide obtained using the sample-and-
separate method at 37ºC (n=3).  The dissolution medium was replaced every 5 days.  
3.3.3. Accelerated in vitro release testing of naltrexone microspheres 
Different strategies (such as extreme pH, and elevated temperature) have been utilized to 
accelerate drug release from PLGA microspheres [9-11]. Elevated temperature conditions can 
increase polymer erosion [14] as well as drug diffusion by increasing molecular mobility [28], 
consequently resulting in accelerated drug release within a short period of time. However, it has 
been shown in Figure 2 that elevated temperature (45°C) resulted in increased naltrexone 
degradation. In order to develop a suitable fast quality control method for naltrexone 
microspheres, both frequent media replacement (every 12 h) as well as the use of 0.0625% (w/v) 
sodium ascorbate in the release medium (10 mM PBS, pH 7.4) without media replacement were 
investigated using USP apparatus 4. As shown in Figure 7, naltrexone release from Vivitrol® 
was dramatically accelerated at 45°C, and the release testing duration was significantly reduced 
from 35-40 days (“real-time”, at 45°C) to around 6 days at 45°C in both cases. Moreover, the 
addition of 0.0625% (w/v) sodium ascorbate in the release medium successfully prevented 
naltrexone from degradation during accelerated release testing. The accelerated in vitro release 
profile obtained in the release medium containing 0.0625% (w/v) sodium ascorbate without 
media replacement was almost identical to that obtained with frequent media replacement. Based 
on these results, 0.0625% (w/v) sodium ascorbate was added to the release media during the 
elevated temperature accelerated release testing at 45°C. The reproducibility of the developed 
accelerated USP apparatus 4 method was also investigated. As shown in Figure 8, in vitro 
release profiles of Vivitrol® (Batches A and B) obtained at different testing dates almost 




Figure 7. In vitro release profiles of Vivitrol® in 10 mM PBS (pH 7.4) containing 0.02% (v/v) 
Tween 20 and 0.02% (w/v) with or without an antioxidant (sodium ascorbate) obtained using 
USP apparatus 4 at 45°C (n=3). The medium without sodium ascorbate was replaced every 12 h 
while the medium with sodium ascorbate was not replaced during testing. 
 
Figure 8. In vitro release profiles of different batches of Vivitrol® in 10 mM PBS (pH 7.4) 
containing 0.02% (v/v) Tween 20, 0.02% (w/v) sodium azide and 0.0625% (w/v) sodium 
ascorbate obtained using USP apparatus 4 at 45°C (n=3). 
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periods of time, which may affect the time for batch release of product as well as delay the 
product development process. Accordingly, an accelerated in vitro release method with good 
correlation with “real-time” in vitro release is essential. As shown in Figure 9, the time-scaled 
“real-time” release profile overlapped with the respective accelerated release profile obtained 
using USP apparatus 4. A linear correlation between the fractions released under “real-time” 
(time-scaled, scaling factor: 6.5) and accelerated conditions was observed for the USP apparatus 
4 method with a regression coefficient (R2) above 0.99. This suggested that the drug release 
mechanisms (the combination of polymer erosion and drug diffusion) at both temperatures may 
be similar. 
  
Figure 9. In vitro release profiles of Vivitrol® in 10 mM PBS (pH 7.4) at 37 °C (time-scaled) 
and at 45°C using the developed USP apparatus 4 method (n = 3). Insert figure shows linear 
correlation between “real-time” (time-scaled, scaling factor: 6.5) (37°C) and accelerated (45°C) 
fraction of naltrexone released. 
It has been previously reported that manufacturing changes (such as solvent systems, and 
emulsification processes) can affect microsphere physicochemical characteristics, which in turn 
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vitro release testing methods that are capable of detecting changes in in vitro release 
characteristics resulting from changes in the manufacturing process. The capability of the 
developed accelerated USP apparatus 4 method to differentiate naltrexone microspheres with 
manufacturing differences was investigated. Compositionally equivalent naltrexone 
microspheres were prepared using different manufacturing processes. It can be seen in Table 1 
that all the prepared naltrexone microspheres had similar drug loading (~29%, w/w), despite 
different manufacturing processes. Since different particle size reduction techniques were used, 
the prepared naltrexone microspheres had different particle size and particle size distribution. 
Furthermore, the prepared naltrexone microspheres showed different porosity, indicating that 
these microspheres may have different internal structures as a result of differences in the 
dynamic solvent exchange processes during microsphere solidification. No significant 
differences were observed in the Tg of the microspheres, and the physical mixture of the drug and 
the PLGA polymer (ca. 42 °C). Due to the differences observed in their critical quality attributes 
(such as particle size and porosity), these microsphere formulations possessed different “real-
time” in vitro release characteristics [29]. The discriminatory ability of the developed elevated 
temperature USP apparatus 4 method was assessed using these microsphere formulations with 
different in vitro release characteristics.  






D50 (Mean ± SD) (μm) 
    Population Volume 
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Formulation 1 DCM&BA 28.74±1.64 49.83 42.93±9.69 121.11±3.61 
Formulation 2 EA&BA 29.7±1.11 58.32  53.93±5.27 105.49±8.63 
Formulation 3 EA&BA 29.57±1.75 65.08 44.32±2.07      68.56±1.52 
Vivitrol® - 33.50±1.43 50.21 58.46±6.01 108.49±1.52 
* BA: benzyl alcohol, EA: ethyl acetate, DCM: methylene chloride 
 
Figure 10. In vitro release profiles of the prepared naltrexone microspheres in 10 mM PBS (pH 
7.4) containing 0.02% (v/v) Tween 20, 0.02% (w/v) sodium azide and 0.0625% (w/v) sodium 
ascorbate using USP apparatus 4 at 45°C (n=3). 
As shown in Figure 10, the accelerated USP apparatus 4 method was capable of 
discriminating the prepared compositionally equivalent naltrexone microspheres with 
manufacturing differences. Drug release from the prepared microspheres reached a plateau 
around day 6 (Formulations 1 and 2) and day 4 (Formulation 3). Accelerated release profiles of 
all the prepared naltrexone microsphere formulations followed the same rank order as their “real-
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and 30 days (Formulation 3) to within 6 days under accelerated conditions. The fraction released 
under accelerated testing conditions were compared with that under “real-time” testing 
conditions (after time scaling) for all the prepared naltrexone microspheres. As shown in Figure 
11, the time-scaled “real-time” release profiles overlapped with their respective accelerated 
release profiles for all the prepared naltrexone microsphere formulations investigated. A linear 
correlation was obtained between the time-scaled “real-time” and accelerated fraction released 
with a regression coefficient (R2) of >0.98. This suggested that the release mechanisms at both 
temperatures may be similar. These results demonstrated the developed accelerated USP 
apparatus 4 method is both discriminatory and reproducible.  Accordingly, it can be used as a 
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Figure 11: In vitro release profiles of Formulations 1, 2 and 3 in 10 mM PBS (pH 7.4) at 37°C 
(time-scaled) and at 45°C using the USP apparatus 4 method (n = 3). Insert figures show linear 
correlations between “real-time” (time-scaled) (37°C) and accelerated (45°C) fractions of 
naltrexone released. (A) Formulation 1; (B) Formulation 2; and (3) Formulation 3. 
3.4. Conclusion 
A reproducible accelerated release testing method with discriminatory ability was developed using USP 
apparatus 4 for compositionally equivalent naltrexone loaded polymeric microspheres with manufacturing 
differences for the first time. The degradation of naltrexone was prevented using frequent media 
replacement and anti-oxidant containing media during “real-time” and accelerated release testing, 
respectively. The accelerated in vitro release profiles of naltrexone microspheres correlated well with 
their respective “real-time” release profiles, indicating that the drug release mechanism(s) may be similar 
under both release testing conditions. Overall, the developed accelerated USP apparatus 4 release testing 
method has demonstrated the potential of being a fast quality control tool that will assure the product 
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Peptide loaded PLGA microsphere products are more complex in terms of manufacturing, 
drug release characteristics as well as release mechanism compared to small molecule loaded 
PLGA microsphere products. This is due to the complex structure of peptides, their 
hydrophilicity, charged state, large size and potential for instability. Moreover, therapeutic 
peptides are highly potent and therefore, any unintended change in the microsphere release 
profile may lead to undesirable side effects and toxicity. Accordingly, the objectives of the 
present work were: 1) to evaluate the impact of minor manufacturing changes on the quality and 
performance of peptide microspheres; and 2) to investigate the feasibility of developing Level A 
in vitro-in vivo correlations (IVIVCs) for peptide microspheres. Compositionally equivalent 
leuprolide acetate (LA) microspheres prepared with minor manufacturing changes (solvent 
system/homogenization speed) showed significant differences in their physicochemical 
properties (such as pore size, total porosity, particle size and surface distribution of peptide on 
the prepared microspheres). This, in turn, resulted in significant alteration in the release 
characteristics. Peptide-polymer interaction, in vitro degradation and microsphere morphology 
studies were conducted to facilitate understanding of the differences in the drug release 
characteristics. A rabbit model was used to determine the pharmacokinetic profiles of all the 
prepared formulations. The obtained in vivo release profiles showed the same rank order as the in 
vitro release profiles but with low burst release and overall faster in vivo release rates. The low in 
vivo burst release is considered to be due to the masking effect of the absorption phase from the 
intramuscular site, and this complicated the development of an IVIVC. Despite these challenges, 
an affirmative Level A IVIVC over the entire release profile was successfully developed for 
peptide microspheres for the first time. This work highlights the feasibility of developing 
IVIVCs for complex parenteral drug products such as peptide microspheres. In conclusion, these 
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results indicate the sensitivity of peptide release, and hence, the safety and efficacy of highly 
potent peptide microspheres, to minor manufacturing changes. Accordingly, development of 



















As per the U.S. FDA guidance1, an in vitro-in vivo correlation (IVIVC) is a predictive 
mathematical model describing the relationship between an in vitro property (e.g. rate or extent 
of drug release) of a dosage form and a relevant in vivo response (e.g. plasma drug 
concentration or amount of drug absorbed vs time).  Despite the successful commercialization of 
various types of extended release microsphere drug products and their increasing popularity in 
the past few decades2, there have been few reports on the development of IVIVCs. Most of the 
reported literature is “proof-of-concept” research demonstrating the possibility of developing 
IVIVCs for microspheres3-9. This is because the development of IVIVCs for long-acting 
polymeric microspheres is very challenging principally due to their complex drug release 
characteristics and the lack of standard bio-predictive in vitro release testing methods10-13   as well 
as the lack of regulatory guidance. Despite these challenges, our group has recently developed a 
1:1 linear correlation, Level A1 IVIVC  (the most affirmative type of IVIVC with the potential to 
be used to obtain biowaivers) for microsphere drug products containing a variety of small 
molecules 14,15. These microsphere products had tri-phasic and bi-phasic in vitro release profiles 
with and without a lag phase, respectively but with low burst release (i.e. Type-I and Type-II 
release profiles, Figure 1). Figure 1 is representative of the different types of release profiles 
typically observed with PLGA microsphere products. Compared to the release Types I and II, the 
release Type III PLGA microspheres have a high burst release followed by slow and continuous 
release. To further explore the concept and achieve a comprehensive understanding of the 
development of IVIVCs for PLGA microspheres, it was considered essential to investigate the 
feasibility of developing IVIVCs for the release Type III microsphere drug products. Typically, 
microspheres containing hydrophilic drug molecules (peptides and small molecules) tend to have 
higher burst release (Type III). Moreover, peptides have complex structure, charged state and 
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larger size compared to small molecules and therefore, peptide microspheres have more complex 
release mechanisms compared to small molecule microspheres. This may result in variations in 
drug release under in vivo conditions compared to in vitro conditions, complicating the 
development of IVIVCs for peptide microspheres. There have been no reports to date on the 
development of Level A IVIVCs for compositionally equivalent peptide microspheres.  
 
Figure 1: Schematic representation of 
typically observed drug release profiles of 
PLGA microspheres. 
Type I – Low burst release phase followed 
by lag phase and secondary release phase 
Type II – Low burst release phase 
followed by secondary release phase 
Type III – High burst release phase 
followed by secondary release phase 
Peptide microsphere products are also more complex in terms of manufacturing as a result of 
the hydrophilic nature, large size and relative instability of peptides. Moreover, due to 
differences in the physicochemical properties of peptides and small molecules, the impact of 
minor manufacturing changes on the quality and performance of peptide microspheres may be 
more or less significant compared to small molecule microspheres. In addition, therapeutic 
peptides are highly potent and hence, any unintended minor changes in the release profiles may 
lead to undesirable side effects and toxicity. Accordingly, it is crucial to understand the impact of 
minor manufacturing changes on the physicochemical properties (quality) and release 
characteristics (performance) of compositionally equivalent peptide microsphere drug products.  
The therapeutic peptide, leuprolide acetate (LA) was chosen as the model peptide since it is 
commercially available in the microsphere drug product, Lupron Depot® (RLD). This product is 































versions. Therefore, it is critical for the industry as well as the regulatory authorities to 
understand the impact of manufacturing differences on the quality and performance of LA 
microsphere drug products. An additional aspect is that this product is prepared using a low 
molecular weight (M.wt.) PLGA16-17, and there have been no studies investigating the impact of 
minor manufacturing changes on the performance of such microspheres. Since this product 
contains positively charged peptide and the polymer is negatively charged at pH 7.4, there is 
potential for charge–charge interaction to affect drug release18. Hence, this study will provide 
important insights into the impact of manufacturing differences on the release mechanism of 
such complex microsphere products. 
The objectives of the present work were to evaluate the impact of minor manufacturing 
changes on the physicochemical properties and drug release characteristics as well as to 
investigate the feasibility of developing a Level A IVIVC for compositionally equivalent 
parenteral microsphere products containing a peptide drug. Leuprolide acetate (LA) was chosen 
as the model peptide. Four compositionally equivalent LA microspheres were prepared with 
manufacturing differences and characterized for various physicochemical properties (such as 
drug loading, particle size, porosity, morphology and M.wt.). The in vitro release characteristics 
of the prepared LA microsphere formulations and the RLD product were determined using the 
developed in vitro release testing method. The pharmacokinetic profiles of the LA microspheres 
were investigated using a rabbit model. The in vivo profiles were deconvoluted using the Loo-
Riegelman method and compared with the respective in vitro release profiles to investigate the 
possibility of establishing an IVIVC. 
4.2. Material and Methods 
4.2.1. Materials  
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PLGA (Resomer® Select 7525 DLG 2CA) was purchased from Evonik (Birmingham, AL). 
Leuprolide Acetate (LA) and reference standard (i.e. LHRH Acetate salt) were purchased from 
Bachem Americas, Inc (Torrance, CA). Poly (vinyl alcohol) (PVA, M.wt. 30-70 kDa) and 
trifluoroacetic acid (TFA) were purchased from Sigma-Aldrich (St. Louis, MO). HPLC-grade 
Methylene chloride (DCM), methanol (MeOH), acetonitrile (ACN) and ACS-grade dimethyl 
sulfoxide (DMSO) were purchased from Fisher Scientific (Pittsburgh, PA). LC-MS grade 0.1% 
v/v formic acid in water, 0.1% v/v ammonium acetate in water and acetonitrile were purchased 
from VWR (Radnor, PA). Milli-Q® water was used for all studies. All other chemicals were 
obtained commercially as analytical-grade reagents. 
4.2.2. Preparation of leuprolide acetate microspheres 
PLGA (M.wt ~15KDa) with a similar molecular weight as that used in the commercial 
product, Lupron Depot®, was used to formulate compositionally equivalent LA microsphere 
formulations using different manufacturing processes. Briefly, 200 mg of PLGA was dissolved 
in methylene chloride (45%, w/v). LA is poorly soluble in methylene chloride and accordingly, a 
co-solvent (such as methanol and DMSO) was used to facilitate the dissolution of LA. The LA 
solution was then added to the polymer solution to form the organic phase and mixed via 
vortexing. The organic phase containing both the polymer and drug was then dispersed into a 
0.35% (w/v) PVA solution (0.22 µm membrane filtered) to form an oil-in-water (o/w) emulsion 
using a homogenizer ((IKA® Works, Inc.) set at 14,000 rpm for 10 seconds followed by 13,000 
rpm for 90 seconds. Leuprolide acetate microspheres with large particle size were prepared using 
a lower emulsification/size reduction force (homogenizer set at 9000 rpm for 10 seconds 
followed by 8000 rpm for 90 seconds). The resultant o/w emulsion was stirred at 400 rpm for 3 h 
under vacuum at room temperature to allow microsphere solidification and solvent evaporation. 
 
 70 
The resultant microspheres were collected, washed using distilled water and dried via 
lyophilization. 
4.2.3. Characterization of LA microspheres 
4.2.3.1. High performance liquid chromatography (HPLC) analysis 
The quantification of LA was conducted using an Agilent HPLC system (series 1200) with a 
UV absorbance detector set at 220 nm (release test samples)/280 nm (drug loading test samples). 
The mobile phase consisting of 0.1% (v/v) tri-fluoroacetic acid in water (A) and acetonitrile (B) 
was used for separation of LA through gradient elution (Table 1) at 30°C. A Kinetex® EVO C18 
column (250 x 4.6 mm, 5μm, 100Å, Phenomenex) was used as the stationary phase. The sample 
injection volume was 20 µL for drug loading and 50 µL for in vitro release testing sample 
analysis. The chromatographs were analyzed using an Agilent OpenLAB chromatography data 
system.  
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4.2.3.2. Drug loading 
The LA microspheres (~5 mg) were weighed and transferred into 10 mL volumetric flasks. 
DMSO (2 mL) was added into the volumetric flasks and the samples were sonicated until all 
particles were dissolved. Methanol was used to dilute the samples. The solutions were filtered 
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(Millex® HV, 0.22 µm PVDF syringe filter) and the LA concentrations were determined via the 
validated HPLC assay as described above. All the measurements were conducted in triplicate and 
the results are reported as the mean ± SD. Drug loading was calculated as:  
Drug Loading (%) =  
weight of drug entrapped
weight of microspheres analyzed
 ×  100 
4.2.3.3. Particle size and size distribution  
Particle size and particle size distribution of the LA microspheres were measured using an 
AccuSizer autodiluter particle sizing system (Nicomp, Santa Barbara, CA). Briefly, the 
microspheres were dispersed in a filtered 0.1% (w/v) PVA solution in water to ensure good 
dispersion, and then particle size analysis was conducted. All the measurements were conducted 
in triplicate and the results are reported as the mean size ± SD. 
4.2.3.4. Morphology  
The morphology of the LA microspheres was analyzed using scanning electron microscopy 
(SEM). Briefly, dry microspheres were mounted on carbon taped aluminum stubs and sputter 
coated with gold under an argon evaporator at high vacuum. The samples were then observed 
using SEM (NanoSEM 450, Nova). 
4.2.3.5. Porosity  
The porosity of the LA microspheres was determined using a Mercury Porosimeter 
(AutoPore IV 9500, Micromeritics). Briefly, approximately 200 mg of LA microspheres were 
introduced into the porosimeter and tested at a mercury filling pressure starting at 0.53 psi. Total 
% porosity and average pore diameter were recorded. 
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Porosity (%) = (1 −  
Bulk density
Apparent (skeletal)density
) ×  100 
4.2.3.6. Differential scanning calorimeter (DSC) analysis 
The glass transition temperatures (Tg) of the LA microspheres were analyzed using a 
modulated temperature differential scanning calorimeter (MTDSC) (TA Instruments Q2000). 
Briefly, weighed quantity (~ 5-6 mg) of each sample was transferred to standard aluminum pans 
and sealed with aluminum lids. The DSC experiment was performed using a 2°C/min heating 
rate and a modulation amplitude of ± 0.82°C with an 80 s modulation period. All samples were 
subjected to a heat/cool/heat cycle. The results were analyzed by using TA analysis software, and 
the Tg was determined as the glass transition midpoint in the reversing signal. 
4.2.3.7. Molecular Weight  
The molecular weight of the microspheres was determined by gel permeation chromatography 
(GPC; Waters) with an evaporative light scattering detector (ELSD). The mobile phase was 
tetrahydrofuran (THF) with a flow rate of 2 ml/min at 40◦C. Samples were dissolved in THF at a 
concentration of 1 mg/mL and filtered (0.45 μm filter, Millipore, USA) before injection into the 
GPC system. The data collection and analysis were performed using Waters Millenium software. 
Polystyrene standards (2000, 900, 824, 400, 200, 110, 43, 18.80, 17.60, 6.93, 2.61, 0.98 kDa) 
were used for calibration and weight average molecular weights (M.wt.) were calculated. All 
measurements were conducted in triplicate and the results are reported as the mean ± SD. 
4.2.4. Peptide-polymer interaction study: 
FT-IR spectroscopy was performed using a Nicolet FTIR (iS5 FTIR, Thermo Scientific) 
spectrometer attached with an attenuated total reflectance (ATR) accessory. Briefly, the samples 
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were placed on the crystal window (Germanium) and compressed lightly using a pressure clamp. 
Spectra were recorded over a range of 400–4000 cm-1 with a resolution of 4 cm-1, for 128 parallel 
scans and evaluated for any shifts in the functional peaks. Data analysis was performed using 
Omnic software (Thermo Nicolet Corporation). The physical mixture was prepared using an 
accurately weighted quantity of drug and polymer in a ratio same as that of the drug loading of 
prepared LA micrspheres (Polymer: drug, 92:8 % w/w). 
4.2.5. In vitro release studies 
In vitro release testing of the LA microspheres was conducted using a developed sample-and-
separate method at 37°C. Briefly, 6 mg of microspheres were dispersed in 1 mL of phosphate 
buffered saline (PBS containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide, 33mM, 
pH 7.4) in low protein binding eppendorf tubes mounted on a rotator set at 100 rpm and 
incubated at 37 °C. At pre-determined time intervals, release media was collected and 
centrifuged at 3,000 rpm for 3 min. Supernatants (0.3 ml) were filtered through 0.22 μm filters 
and analyzed via HPLC. The release media was replaced with fresh media at each sampling time 
point. Media replacement during release testing was taken into account in the calculation of the 
% cumulative release. All drug release tests were conducted in triplicate and the results are 
reported as the mean % cumulative release ± SD. 
4.2.6. In vitro degradation studies 
An exhaustive in vitro degradation study of the LA microspheres was conducted similar to 
the in vitro release testing method. At pre-determined time points, microsphere samples 
incubated under release testing conditions were collected, washed, lyophilized and evaluated for 
polymer molecular weight using gel permeation chromatography (GPC) and morphology using 
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scanning electron microscopy (SEM) as mentioned above. 
4.2.7. In vivo release studies 
The in vivo release characteristics of the LA microspheres were investigated using a rabbit 
model. Briefly, male rabbits (New Zealand White, n = 6) weighing approximately 3 to 4 kg were 
randomly assigned to each treatment group i.e. formulation. The LA microspheres were 
suspended in the diluent used for dispersion of the commercial product Lupron Depot® and 
injected into the rabbit hind leg thigh muscles at a dose of 2.14 mg/kg. In addition, a 
pharmacokinetic study of the LA solution in saline (dose: 0.025mg/kg, i.v.) injected via the 
intravenous route was conducted (n = 6) to determine the PK parameters of LA in rabbit. Blood 
samples were collected from the marginal ear veins at predefined time intervals. The collected 
blood samples were centrifuged at 14,500 rpm for 5 min to separate out the plasma. The plasma 
was collected and stored at -80°C until analysis. The animal study protocol was reviewed and 
approved by the University of Connecticut's Institutional Animal Care and Use Committee 
(IACUC) prior to the beginning of the experiments. 
4.2.8. Plasma sample analysis 
LA ((Des-Gly10, D-Leu6, Pro-NHEt9)-LHRH, M.wt. 1209.42 Da) was extracted from plasma 
samples using a protein precipitation extraction method. LHRH ((Des-Gly10, D-Ala6, Pro-
NHEt9)-LHRH, M.wt. 1167.34 Da) acetate salt was used as the internal standard (IS). Briefly, 
100 μl of plasma samples were mixed with either 100 μl of LA solution in diluent (0.1% formic 
acid in water: acetonitrile (90:10, %v/v)) for the preparation of calibration standards (1, 2.5 5, 10, 
15, 20 and 30 ng/ml) or 100 μl of diluent for study samples. All the samples were then spiked 
with 20 μl of the IS solution (200 ng/ml in methanol). Ice-cold acetonitrile was then added in a 
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stepwise fashion (two-steps, each of 500 μl) to the pre-treated plasma samples and vortex-mixed 
for 10 minutes at 2,500 rpm followed by centrifugation at 14,500 rpm (4°C) for 8 minutes. The 
supernatants were transferred to the low-protein binding polypropylene (PP) centrifuge tubes and 
dried under nitrogen at 40°C. The dry residues were then reconstituted in 100 μl of diluent (0.1% 
formic acid in water/acetonitrile, 90:10 %v/v). 25 μl of the reconstituted solution was used for 
LC-MS/MS analysis. Please note that during the entire preparation process, plasma samples were 
processed in the ice bath before the collection of supernatant samples for drying.  
The LC-MS/MS system consisted of an Agilent HP-1100 LC system and a TSQ Quantum 
Ultra Mass Spectrometer (Waters) with an electrospray ionization (ESI) ion source. 
Chromatographic separations were carried out on a Kinetex EVO C18 column (50 x 2.1 mm, 2.6 
μm, 100 Å) through gradient elution (Table 29) at 35°C. The following MS detection parameters 
were used: 4400 V electrospray voltage, 320°C capillary temperature, and 35 V collision energy. 
Detection of ions was conducted in the positive-ion selected reaction monitoring mode with the 
following transitions in a single reaction monitoring (SRM) mode: m/z 605.5 to 249.1 for 
leuprolide acetate, and 584.67 to 249.1 for the IS. The injection volume was 25 μl. The data 
acquisition was ascertained by Xcalibur software. Calibration curves were established on each 
day when analysis was conducted and showed good linearity with correlation coefficients > 0.99. 
The lowest limit of quantification (LLOQ) for LA was 1 ng/mL and the mean recovery of plasma 
samples from low to high concentrations of LA was more than 90%. The inter- and intra-day 
variations of the three different concentrations of naltrexone (1, 10, and 30 ng/mL) were less 
than 15%. 








0.1% formic Acid/0.1% ammonium 
acetate (21/, v/v), % 
ACN, % 
0 0.3 95 5 
5 0.3 40 60 
8 0.3 40 60 
9 0.3 95 5 
12 0.3 95 5 
4.2.9. Pharmacokinetic (PK) analysis and the development of an IVIVC 
The development of IVIVC for the prepared LA microspheres was performed using a two 
stage deconvolution approach following the same principles as detailed in the U.S. FDA 
guidance on the development of IVIVC for extended release oral dosage forms 1. Briefly, the in 
vivo plasma profiles of LA microspheres were deconvoluted using the Loo-Riegelman 
method 12,19. Standard errors are not shown in the deconvoluted in vivo absorption profiles 
because the average plasma concentration values were used. The fraction absorbed in vivo was 








Cp, Ct, K10, and AUC are the drug concentration in the central compartment (plasma), 
apparent tissue compartment concentration, elimination rate constant and area under the plasma 
vs time curve, respectively. The distributive and elimination micro rate constants (k12, k21 and 
k10) that are necessary for calculating Ct, and the total fraction absorbed at time t, were calculated 
using a two compartment model, PK analysis tool, WinNonlin® 6.4 (Pharsight, Certara 
Corporation, St.Louis, USA) from the plasma concentrations vs time profiles of LA solution after 
single intravenous administration in rabbits. Similarly, PK parameters of all the LA microsphere 
formulations were determined using non-compartmental analysis. The development and 
validation of the IVIVC for the LA microspheres were performed using the IVIVC toolkit, 
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WinNonlin® 6.4 (Pharsight, Certara Corporation St.Louis, USA).  
4.2.10. Statistical data analysis 
Statistical analysis was performed to evaluate significant differences between different 
microsphere formulations using a paired student t-test. The level of significance was accepted 
at p < 0.05. 
4.3. Results and Discussion: 
4.3.1. Physicochemical properties of the LA microspheres 
Four LA microsphere formulations (i.e. F1, F2, F3 and F4) with Q1/Q2 equivalency were 
prepared with minor manufacturing changes (such as cosolvents and homogenization speed) and 
evaluated for differences in physicochemical properties, if any. The RLD product (Lupron 
Depot® (one month)) was used as a control. As shown in Table 3, the drug loading of the RLD 
product was around 7% (w/w) and all the prepared LA microsphere formulations had similar 
drug loading of around 8% (w/w). This shows that the prepared LA microsphere formulations 
were Q1/Q2 equivalent despite minor changes in the manufacturing process. 
Table 3. Drug loading of the RLD and the LA microspheres prepared with minor manufacturing 
changes. 
Sample Preparation Parameters Drug Loading (%, w/w) 
RLD - 6.88±0.77 
F1 




Homogenization (DCM/methanol: 2.6/1, 
w/w) (large particle size) 
8.55±0.08 
F3 Homogenization (DCM/DMSO: 3.7/1, w/w) 8.47±0.14 
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F4 Homogenization (DCM/DMSO: 3.7/1, w/w) 
(large particle size) 
8.14±0.01 
The mean particle size and size distribution of the prepared LA microspheres and the RLD 
product were evaluated. As shown in Figure 2, all the prepared LA microsphere formulations 
had larger particle size in terms of volume distribution and smaller or equal particle size in terms 
of population distribution when compared to the RLD product. This, in turn, indicates a wide 
size distribution (Figure 2B) in all the prepared microsphere formulations compared to the RLD 
product. Moreover, formulations F1 and F3, prepared using similar homogenization speeds and 
time, did not show significant differences in the particle size despite the use of different solvent 
systems. This indicates that the impact of the solvent system on droplet size during 
emulsification and of solvent evaporation rate during microsphere solidification on the final 
particle size was not significant (p>0.05). However, formulations F2 and F4 had a larger mean 
particle size in terms of volume distribution compared to formulations F1 and F3 prepared using 
the same solvent system (Figure 2). This is due to the use of lower homogenization speed during 
the emulsification process20,21.  
  
Figure 2. Particle size and size distribution of the RLD product and LA microsphere 
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value. All values are expressed as mean ± SD (n=3).  
As shown in Figure 3A, some irregular shapes (indicated by the blue arrow) and a highly 
porous polymer matrix (indicated by the red arrows) were observed for the RLD product. On the 
other hand, the prepared LA microspheres showed a spherical shape with a smooth surface 
(Figures 3B to 3E). Compared to formulations F1 and F2, formulations F3 and F4 showed a 
more porous structure, which may be due to the different solvent systems used in processing. 
Different solvent systems also lead to changes in the polymer precipitation rate. For example, 
PLGA is more soluble in DCM/DMSO compared to DCM/methanol. Moreover, DMSO has a 
higher boiling point and hence, will be removed slowly compared to methanol. Taken together, 
these differences will lead to relatively slower solidification into microspheres for formulations 
F3 and F4 compared to formulations F1 and F2, allowing more dynamic solvent exchange and 
entrapment inside the microspheres. The removal of the entrapped solvents during drying will 
create pores and hence, formulations F3 and F4 have more porous structures compared to 
formulations F1 and F2.  
 
Figure 3. SEM images of the RLD product and leuprolide acetate microsphere formulations. 
Symbol: The green arrow points to the irregular shapes of microspheres and the red arrows 
F4                                                E 
F5                                                 F 
50 μm 5 μm
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point to pores in the microsphere matrix. 
The observed differences in the porous structure of the prepared microsphere formulations 
were further confirmed and quantified by evaluation of the % porosity of the LA microsphere 
formulations. As shown in Table 4, overall differences in the total % porosity of the 
formulations were observed with F3 being the most porous and F2 being the least porous/more 
dense formulation. In agreement with the morphological characteristics (Figure 2), formulations 
F3 and F4 had relatively higher % porosity compared to formulations F1 and F2.  
Since LA is a peptide of relatively higher molecular weight/larger size compared to small 
molecules, it is reported that the pore diameter can also be a critical parameter controlling 
diffusion out of microspheres into the release medium22. Accordingly, the average pore diameter 
of the prepared LA microsphere formulations was investigated. As shown in Table 4, significant 
differences in the average pore diameter of all the prepared formulations were observed with F2 
having the smallest pore diameter and F3 having the largest pore diameter. The pore diameters of 
formulations F1 and F2 were smaller than F3, which shows that the differences in the solvent 
systems leads to differences in the pore diameter. In addition, despite the use of the same solvent 
systems, the pore diameters of formulations F2 and F4 (smaller particle size microspheres) were 
smaller than those of formulations F1 and F3 (larger particle size microspheres), respectively. 
Similarly, the % porosity of formulations F2 and F4 was smaller than that of formulations F1 and 
F3. These results indicate that particle size, in addition to the solvent system, has the potential to 
alter the % porosity and pore diameter. It has been reported that faster solvent removal and 
polymer precipitation leads to the formation of large pores23. Since diffusion distance will be 
relatively shorter in small particles compared to larger particles, solvent exchange and solvent 
removal will be faster for small particles compared to large particles.  
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Tg (°C) Molecular Weight (D) 
(Mean ± SD) 
F1 57.06 814.5 44.1 13245±173 
F2 52.65 712.7 45.32 13406±41 
F3 61.01 964 44.78 13541±22 
F4 56.48 814.1 45.27 13550±60 
As shown in Table 4, no significant differences in the Tg and polymer molecular weight of 
the prepared LA microsphere formulations were observed for the minor manufacturing changes 
investigated. However, the physicochemical properties of LA microspheres (such as particle size, 
morphology, pore size, and % porosity) are sensitive to the minor manufacturing differences. 
4.3.2. In vitro release characteristics of the LA microspheres   
The in vitro release testing method was developed by screening different methods and 
conditions (such as membrane dialysis vs sample and separate methods, buffer strength, media 
replacement), with the aim to achieve 100% cumulative drug release as well as to maintain 
peptide stability throughout the release study (data not shown). As shown in Figure 5A, 100% 
drug release was achieved using the sample-and-separate in vitro release testing method. In 
addition, the method had good reproducibility with less than 5% RSD at all time points (Figure 
5A). As shown in Figure 5B, the in vitro release method was also able to discriminate changes 
in the drug release characteristics of the LA microsphere formulations prepared using minor 
manufacturing changes as well as the RLD product. Overall, all formulations appeared to follow 
biphasic release characteristics with an initial burst release phase followed by an apparent zero-
order slow release phase over a period of at least 40 days.  
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Differences in the drug release profiles, especially the burst release phase (from 10% to 39% 
in 24 h) were observed for the formulations. Variable burst release is a result of differences in the 
amount of surface associated drug, which may be due to one or the combination of the following 
factors: 1) higher solubility of PLGA in DCM/DMSO compared to DCM/MeOH; and 2) slower 
evaporation of DMSO compared to MeOH. These two factors result in slower microsphere 
solidification and hence, more drug diffusion onto the surface of formulations F3 and F4 
compared to F1 and F2. In addition, the higher solubility of LA in DMSO compared to MeOH 
leads to greater accumulation of drug onto the surface of formulations F3 and F4 during solvent 
exchange. Moreover, formulations F1 and F3 have small particle size compared to formulations 
F2 and F4, resulting in the higher surface area to volume ratio and hence, a greater amount of 
surface associated drug leading to higher burst release.  
In addition to the burst release phase, differences in the release rate of all the LA 
microspheres were observed over the initial 15-day period (Figure 4B). Formulation F3 had the 
highest % porosity with the largest average pore diameter (Table 4) leading to greater peptide 
diffusion and hence, a faster release rate compared to other formulations. Whereas formulation 
F2, which exhibited the lowest porosity with the smallest average pore diameter (Table 4), 
showed the slowest release rate. Moreover, formulations F2 and F4, which have larger particle 
size and hence greater diffusion distance, exhibited slower release than formulations F1 and F3.  
The RLD product, which is prepared using a gelatin based double emulsion method showed 
higher burst release than all the prepared formulations. This may be due to the smaller particle 
size (Figure 2) of RLD compared to the prepared formulations leading to higher amount of 
surface associated drug. Moreover, the release profile of the RLD was tri-phasic, which may be a 




Figure 4A. In vitro release profiles of 
different batches of formulation F1 obtained 
on different testing dates using the sample-
and-separate method at 37°C (n=3). The 
medium (33 mM PBS contaning 0.02% w/w 
sodium azide and Tween 20, pH 7.4) was 
replaced every two to three days. 
 
  
Figure 4B. In vitro release profiles of 
compositionally equivalent LA 
microspheres prepared with minor 
manufacturing changes and the RLD 
product obtained using the sample-and-
separate method at 37°C (n=3). The 
medium (33 mM PBS contaning 0.02% 
w/w sodium azide and Tween 20, pH 7.4) 
was replaced every two to three days. 
 
Peptide polymer interaction study:  
To further understand the impact of manufacturing differences on the drug release characteristics 
and the underlying release mechanism(s) of the prepared LA microspheres, peptide-polymer 
interactions as well as microsphere in vitro degradation were investigated. 
It has been reported18 that LA is a positively charged peptide at neutral or lower pH, with the 
potential to interact with the negatively charged carboxylic acid end groups in PLGA (pKa 
~3.8)24. This can result in the adsorption of LA within the microspheres PLGA matrix leading to 































































































physicochemical interaction between LA and PLGA controls drug release18, any unintended 
change to this interaction may result in undesirable changes in the drug release rate and duration. 
For example, solvents (DCM/DMSO/MeOH) have the potential to alter the physicochemical 
interaction between LA and PLGA during the manufacturing process. This in turn may alter 
peptide distribution as well as peptide-polymer interaction, resulting in alteration of the release 
characteristics.  
FT-IR spectra of PLGA and LA in formulations F1 and F3 (prepared using different solvent 
systems) were evaluated for any changes (shift in the wavenumber or intensity) in their 
characteristic absorbance bands (Table 5) compared to pure LA, PLGA and their physical 
mixture (Figure 5). As shown in Figure 5B, the intensity of the characteristic bands of LA in the 
physical mixture and the prepared LA microspheres were reduced compared to the pure LA 
spectra (Figure 5A). This is due to the lower amount of LA (8%) compared to PLGA (92%). No 
other significant changes in the spectra of the microsphere formulations (Figure 5A) were 
observed compared to the pure LA, PLGA and the physical mixture (Figure 5B) except for the 
N-H stretching band. This indicates that there is no significant interaction between the drug and 
the polymer except for weak hydrogen bonding (N-H stretching band – 3269, 3323 and 3333 
cm−1 in the physical mixture and formulations F1 and F3, respectively). Moreover, the FT-IR 
spectra of the formulations prepared with different solvent systems (Figure 5A) were also 
similar except for the difference in the N-H stretching band. This indicates that there is no impact 
of the solvent system on LA-PLGA interaction in the dry microspheres, implying that the 
reported physicochemical interaction between LA and PLGA18 possibly occurs only in the 




Table 5. Characteristic FT-IR absorption bands (cm
-1
)  







~2996, 2946 (CH, CH2. CH3 
stretching), ~1745 (ester C=O 
stretching), ~1381, 1423, 1451 (C=O 
bending vibrations), -1268 (C-C(=O)-0 
symmetric/asymmetric stretching), 
1150-1350 (CH2, CH wagging), 
~1082, 1128 (C-O ester stretching) 
LA27 
 
~3269 – broad band (O-H, 
amide/amine N-H stretching), ~2996 
(CH, CH2. CH3 stretching), ~1630 
(amide C=O stretching), ~1535,1514 
(N-H bending), ~1400-1600 (aromatic 
C=C stretching), ~1350-1480 (-CH 


















Figure 5. (A) Overlay of FT-IR spectra of LA, PLGA and physical mixture (LA:PLGA, 8:92% 
w/w) and (B) Overlay of FT-IR spectra of prepared LA microsphere formulations 
F1_DCM/MeOH and F3_DCM/DMSO and physical mixture (LA:PLGA, 8:92% w/w) 
In vitro degradation study:  
Hydrolytic degradation of the PLGA in aqueous release media is one of the major 
mechanisms for drug release from PLGA microspheres. It has been reported14,15,28-29 that 
differences in the particle size and porosity of the prepared microspheres as a result of 
manufacturing differences may lead to an altered surface area to volume ratio and extent of water 
diffusion inside the particles and hence, differences in the polymer degradation rate. This may be 
responsible for the observed differences in the microsphere drug release characteristics. 
Therefore, an in vitro degradation study was conducted to evaluate any difference in the polymer 
degradation kinetics of the microspheres during release testing. However, as shown in Figure 6, 
no significant differences in the polymer degradation rate (as shown by decrease in molecular 
weight) were observed among the microspheres formulations with different size and porosity. 
This may be a result of the faster degradation rate of the low M.wt. PLGA of LA microspheres 
compared to that of previously reported high molecular weight PLGA micropsheres30. Thus, the 
differences in release characteristics of the various microsphere formulations are not due to the 




Figure 6. Degradation kinetics of 
PLGA microspheres prepared with 
minor manufacturing differences under 
in vitro release testing conditions (33 
mM PBS containing 0.02% w/w 
sodium azide and Tween 20, pH 7.4 at 
37°C) 
The diffusion of the peptide from the polymer matrix into the release media is another major 
release mechanism. Microsphere samples from the in vitro degradation study were evaluated for 
impact of morphological differences (such as pore diameter, shape and network) on the 
diffusion-based peptide release. As shown in Figure 7, as degradation proceeded, both 
microsphere formulations appeared to follow the typical “inside-out” degradation mechanism. It 
was evident that the more porous microspheres i.e. formulation F3 degraded faster with 
formation of large pores and channels inside the microspheres by day 15 (as shown by the yellow 
arrow) compared with the less porous microspheres (i.e. formulation F1). The formation of pores 
and channels inside the F1 formulation became evident only after day 15. These differences in 
microsphere structure may be responsible for the observed differences in the drug release rates 
during the initial 15-day period (Figure 4B), especially since LA is large in size and hence, may 
have pore size/structure restricted diffusion and release. After 15 days, polymer erosion 
progressed extensively leading to complete shape deformation and exposure of greater surface 
area.  No significant difference in pore structure and hence, release rate was observed after day 
20 (Figure 4B).  
Similar morphological changes as formulations F1 and F3 were observed for formulations F2 






































Figure 7. SEM images of LA microsphere formulations F1_DCM/MeOH and 
F3_DCM/DMSO under in vitro release testing condition (33 mM PBS containing 0.02% 
w/w sodium azide and Tween 20, pH 7.4 at 37°C) over a period of 50 days. Symbols: the 
red arrows point to pores on the surface of the microspheres; the blue arrows point to 
differences in the indentations on the surface of the microspheres; the yellow arrows point 
to the differences in pore structure. 
4.3.3. In vivo release characteristics of the LA microspheres   
The pharmacokinetic profiles of the LA microspheres following intramuscular (i.m.) 
administration in rabbits are shown in Figure 8. All the prepared compositionally equivalent LA 
microsphere formulations and the RLD product exhibited bi-phasic in vivo release profiles with 
variable burst release phase followed by slow and continuous zero–order release over 40 days. 
The key pharmacokinetic parameters of each microsphere formulation were determined and are 
listed in Table 6. Similar Tmax of 3.5 h with variable Cmax concentrations corresponding to the 
burst release were observed for all formulations and the RLD product (Table 6). Formulation F2 
had the lowest Cmax while formulation F3 had the highest Cmax with F1 and F4 having 
intermediate Cmax. Moreover, formulation F2 had the lowest AUC0-last while F3 had the highest 
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AUC0-last with F1 and F4 having intermediate AUC0-last values. F2 had the longest T1/2 compared 
to all other formulations.  
 
Figure 8. In vivo release profiles 
of the compositionally equivalent 
LA microspheres prepared with 
minor manufacturing changes in a 
rabbit model (i.m. n=6). 











F1 0.15 4.22 66.97 17.73 
F2 0.15 2.87 54.89 23.83 
F3 0.15 7.43 76.30 15.59 
F4 0.15 5.80 74.69 12.42 
Lupron 
Depot® 
0.15 9.49 69.03 24.15 
The differences in the in vivo burst release and release rate are similar to the in vitro release 
profiles of the various formulations and result from differences in their physicochemical 
properties.  
4.3.4. Pharmacokinetic Analysis and development of IVIVC  
4.3.4.1. Pharmacokinetic analysis of LA in rabbits: 
The PK study of the LA solution following single intravenous (i.v.) administration was used 






































constants (k12, k21 and k10), which are necessary for deconvolution of the LA microsphere in vivo 
release profiles into the total fraction absorbed using the Loo-Riegelman method19.  
Table 7. Pharmacokinetic parameters of the LA solution (i.v.) (Software: WinNonlin® 6.4). 











46.34 6.40 4.90 0.39 2.04 2.31 0.93 
4.3.4.2. Deconvolution of the in vivo release profiles of LA microspheres 
The in vivo plasma concentration vs time (PK) profiles (i.m.) of the LA microspheres were 
deconvoluted into the fraction absorbed vs time using the pharmacokinetic parameters (Table 7) 
of LA in rabbits and the Loo-Riegelman deconvolution method19. The deconvolved fraction 
absorbed vs time profiles of the prepared LA microspheres and the RLD product are shown in 
Figure 9. Overall, the deconvolved in vivo LA release from PLGA microspheres appeared to be 
faster compared to their respective in vitro release profiles. This may be due to accelerated 
polymer degradation as a result of local acidic pH and/or the presence of other biological 
components (such as enzymes) in the interstitial tissue fluid at the intramuscular injection site. 
Despite the difference in the in vivo and in vitro release rates, the in vivo release profiles of all 
formulations followed a similar rank order as the in vitro release profiles: RLD>formulation F3 
> formulation F4 > formulation F1> formulation F2. This indicates that the release mechanisms 
under in vitro and in vivo conditions appear to be similar, which is one of the major requirements 
for the development of IVIVCs1. Interestingly, it was observed that the in vivo burst release was 
significantly lower than each respective in vitro burst release. This may be due to the masking 
effect of poor or slow absorption of the peptide into the systemic circulation as a result of 
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hydrophilicity, larger size, steric hindrance and/or charge interaction with the extracellular 
matrix at the intramuscular site.  
Overall, comparison of the deconvoluted in vivo release profiles with the respective in vitro 
release profiles of the LA microspheres suggested the feasibility of developing a point-to-point 
IVIVC model, but with the use of mathematical parameters to account for the difference in the 
release rate and % burst release under in vitro and in vivo conditions.  
 
Figure 9. Deconvolved in vivo profiles 
(fraction absorbed/released) of the 
compositionally equivalent LA 
microspheres prepared with minor 
manufacturing changes (deconvolved 
using the Loo-Riegelman method). 
4.3.4.3. In vitro - in vivo correlation of the LA microspheres   
The U.S. FDA guideline1 recommends the use of a minimum of two, preferably three or more 
formulations with different release rates to define an IVIVC. Therefore, all four prepared LA 
microsphere formulations with different in vitro and in vivo release rates were used in developing 
IVIVC(s) in different combinations of three out of four formulations. Based on the knowledge 
obtained from our previous research on risperidone14 and naltrexone15 microspheres, 
formulations on the extremes of the release profile range (i.e. formulations F2 and F3) were 
included in the different combinations of formulations studied to develop correlation models 
with better predictability and wider application scope. Accordingly, a total of two different 









































the in vitro release profiles were simulated via model fitting using Origin Pro (data analysis 
software) to synchronize the sampling time interval with the in vivo release profiles. Due to the 
differences in the release rate and release duration of the in vitro and deconvoluted in vivo 
release profiles, time scaling (1/1.65) and time shifting (+1) factors (determined using a Levy 
plot - in vivo vs in vitro time for definite fraction released) were used to achieve a 1:1 correlation. 
As recommended by the FDA guidance, the same time-scaling/shifting factors were applied to 
all formulations used for the development and validation of the IVIVCs. The fraction 
absorbed/released in vivo of selected formulations was plotted against the fraction released in 
vitro at the respective time point to establish a correlation if any. As shown in Figure 10 (A and 
D), an affirmative point-to-point correlation i.e. a Level A IVIVC1 between the fractions released 
in vitro and fractions released/absorbed in vivo was observed for all combinations using a simple 
linear regression model (correlation coefficients greater than 0.97). All the developed IVIVCs 
were comparable as manifested by similar slopes and intercepts.  
These developed IVIVCs were then used to predict the in vivo profiles of the fourth 
remaining external formulation using the real time in vitro release profiles. As shown in Figure 
10 (B and E), the predicted in vivo profiles of the external formulations overlapped with the 
observed deconvoluted in vivo release profiles for both IVIVC models, indicating that the models 
are predictable.   
The developed IVIVCs were also used to predict the in vivo release/absorption profile of the 
Lupron Depot®, RLD product from its “real-time” in vitro release profile. As shown in Figure 
10 (C and F), the predicted in vivo release profiles were very similar to the observed 
deconvoluted in vivo profiles obtained in rabbits irrespective of which IVIVC model was used. 
These results showed that the developed IVIVCs were sufficiently robust. Most importantly, the 
 
 93 
developed IVIVCs can be used to predict not only the LA microsphere formulations that are 
equivalent in formulation composition but also a microsphere formulation that is not equivalent 






Figure 10. Level A IVIVC for LA microspheres using the two-stage deconvolution 
y = 0.8828x + 0.0648 




























y = 0.8887x + 0.0633 



























































































































approach based on the Loo-Reigelman method. (A) IVIVC developed using 
formulations F2, F3 and F4 (IVIVC 1). (B) Experimental and predicted in 
vivo release profiles of formulation F1, based on IVIVC 1. (C) Experimental and 
predicted in vivo release profiles of RLD product, Lupron Depot®, based on IVIVC 
1. (D) IVIVC developed using formulations F1, F2 and F3. (E) Experimental and 
predicted in vivo release profiles of formulation F4, based on IVIVC 2. (F) 
Experimental and predicted in vivo release profiles of RLD product, Lupron Depot®, 
based on IVIVC 2 
All the developed IVIVCs were internally as well as externally validated for their 
predictability as per the FDA guidance1. The predictability of the IVIVCs was estimated in terms 
of % prediction error (PE) of Cmax and AUC0-last using WinNonlin
® 6.4 software. As shown in 
Table 8, the average absolute internal % PE for the Cmax (9.52%) of IVIVC 2 was within the 
recommended range of 10% or less. However, the average absolute internal % PE for AUC0-last 
(10.94%) was slightly more than 10%, suggesting the internal predictability of the developed 
IVIVC 2 for the AUC0-last was inconclusive. Accordingly, evaluation of external predictability of 
the IVIVC 2 was performed. As can be seen in Table 8 the external % PE for the Cmax and 
AUC0-last were 1.52% and 2.83%, respectively, which passes the recommended external 
predictability evaluation (% PE of 10% or less). These results indicate that the developed IVIVC 
2 has good external predictability, and thus could be used as a surrogate for bioequivalence 
studies in rabbits.  
Furthermore, the predictability of the developed IVIVC 2 for the RLD was also investigated. 
Both % PEs for Cmax (8.40%) and AUC0-last (-8.31%) were below 10%. These results confirmed 
that the developed IVIVC 2 has potential to be used to predict the in vivo performance of not 
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only the compositionally equivalent LA microsphere formulations with manufacturing 
differences but also LA microsphere formulations that are not compositionally equivalent. 
Moreover, the successful development of the validated IVIVC 2 model also indicates that the 
developed sample-and-separate in vitro release testing method had good predictability of the in 
vivo performance of leuprolide acetate polymeric microspheres. 
Table 8. Validation and prediction of the developed IVIVC_2 for LA microspheres. 
 Cmax (μg/l) AUC0-last (μg/l * day) 
Internal 
validation 
Obs. Pred. %PE Obs. Pred. %PE 
Formulation F1 4.22 3.96 -6.18 66.97 61.42 -8.28 
Formulation F2 2.87 2.38 -16.95 54.89 62.68 14.20 
Formulation F3 7.43 7.02 -5.43 76.30 68.41 -10.34 
Average 
Internal 
4.84 4.45 9.52 66.05 64.17 10.94 
External Validation 
Formulation F4 5.80 5.71 -1.52 74.69 72.58 -2.83 
RLD Prediction       
Lupron Depot® 9.49 10.29 8.40 69.03 63.29 -8.31 
Please note that external % PE for the IVIVC_1 was within the acceptance criteria in terms 
of Cmax (-8.92%) but slightly higher for the AUC0-last (-10.85%). Accordingly, it was not 
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considered a validated IVIVC model although it did not show significant difference in the 
predictability of in vivo profile (Figure 10 B and C).  
4.4. Conclusions: 
The present manuscript describes for the first time that Level A IVIVCs can be developed 
for compositionally equivalent PLGA microspheres containing large molecular weight and 
complex molecules such as peptides. It was observed for the first time that slow absorption of 
peptide at the intramuscular site masked the high burst release that was observed under in vitro 
release testing conditions. This difference in the burst release phase under in vitro and in vivo 
conditions complicated the development of an IVIVC. Accordingly, multiple mathematical 
parameters were needed to achieve a 1:1 linear Level A correlation. Together with our previous 
research on developing Level A IVIVCs for polymeric microspheres containing small molecules, 
it can be concluded that Level A IVIVCs can be developed for a variety of complex parenteral 
microsphere drug products using in vitro release testing methods and a rabbit model. This shows 
the potential of developing IVIVCs using clinical data for such complex parenteral drug 
products, which can serve as surrogates for bioequivalence studies. 
The critical quality attributes and performance of microspheres containing large 
molecular weight and complex molecules such as peptides were shown to be sensitive to minor 
manufacturing changes. This is particularly significant for microspheres containing substantial 
amount of potent drugs such as peptide. It was also shown that the hydrolytic degradation of low 
molecular weight PLGA was not sensitive to differences in particle size and porosity. However, 
the drug release characteristics of such microspheres containing relatively large hydrophilic 
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Abstract:   
Development of IVIVCs is a very complicated process, especially for complex drug products such as 
parenteral PLGA microspheres with multiphasic drug release characteristics. Specifically, microspheres 
that exhibit an initial burst release phase are even more challenging since the in vitro and in vivo burst 
release phases may not be comparable if drug absorption is rate-limiting at this stage. Therefore, the 
objectives of the present work were: 1) to investigate the predictability of IVIVCs for the in vivo burst 
release phase based on the in vitro burst release phase of the formulations; and 2) to evaluate the impact 
of variable burst release on the predictability of the developed IVIVCs for two different types of 
microsphere drug products. Accordingly, Risperdal Consta® (Risperidone) and Lupron Depot® 
(Leuprolide acetate, LA) were selected as model microsphere products. Q1/Q2 equivalent risperidone and 
LA microsphere formulations with variable burst release phases were prepared with manufacturing 
process changes (such as solvent systems and mixing methods). The prepared microspheres had 
differences in critical physicochemical properties (such as particle size, porosity, average pore diameter, 
and drug distribution) and hence differences in their in vitro release characteristics (such as variable burst 
release and release rate). The in vitro and in vivo (rabbit model (i.m.)) burst release were similar for the 
risperidone microspheres but were significantly different for the LA microspheres. This had an impact on 
the complexity of the developed IVIVC models. Level A IVIVCs with the ability to predict various types 
of burst release were developed using time scaling and shifting factors. Moreover, it was observed that 
IVIVCs developed using formulations with less variation in burst release had better predictability and 
vice-versa. Thus, the present research has provided an in-depth understanding of the impact of the burst 
release phase on the development, complexity, and predictability of IVIVCs for complex parenteral 





5.1. Introduction:  
As per the U.S. FDA guiedance1, an in vitro – in vivo correlation (IVIVC) is a predictive 
mathematical model describing the relationship between an in vitro property of a dosage form and a 
relevant in vivo response. It is an important biopharmaceutical tool used in formulation development to: 
speed up the initial screening process; widen dissolution specifications; and most importantly serve as a 
surrogate for in vivo BE studies during initial prodcut development as well as certain scale-up and 
postapproval changes (SUPAC).  However, the development of a predictive and robust IVIVC model is a 
very complex process. To develop an effective IVIVC, the physicochemical and biopharmaceutical 
properties of the drug2 (such as drug solubility, pKa, drug permeability) and dosage form (size, polymer 
type, release characteristics, stability etc.) as well as the physiological environment (pH, fluid volume, 
tissue response, site of absorption etc.) in the body must be taken into consideration. A detailed regulatory 
guidance on various aspects of IVIVC development for extended release oral products is available1. In 
addition, the development of IVIVCs for oral products has been widely investigated and reported in the 
literature, highlighting various critical factors (such as mean vs individual profile, time scaling and 
shifting) that may need to be considered3. 
However, long acting parenteral drug products (such as PLGA microspheres) are more complex and 
significantly different compared to extended release oral products in terms of their release characteristics 
as well as physiological conditions at the site of administration4,5. For example, PLGA microspheres have 
complicated multiphasic release profiles (i.e. burst release phase, lag phase and secondary release phase) 
with different release rates for each phase6-10. Additionally, there are very few reports on the development 
of IVIVCs for such products4. Accordingly, it is essential to investigate specific and critical attributes that 
need to be considered during development of IVIVCs for such complex parenteral drug products. It has 
been reported that the in vivo absorption phase at the intramuscular site can mask high burst release 
observed under in vitro conditions11. In addition, fibrous encapsulation of microspheres through the host 
immune response9,10,12-14 or steric hindrance by the extracellular matrix may lower the in vivo burst 
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release. These factors make it difficult to develop IVIVCs with an ability to predict initial in vivo drug 
release. It was observed during our previous work that IVIVCs developed using formulations with 
significant variations in the burst release phase had limited ability to predict the burst release phase15-16. 
Accordingly, it is essential to investigate formulations with and without a burst release phase, as it may be 
important to distinguish between these different types of formulations when considering the development 
of IVIVCs for microspheres. 
Building on the knowledge and experience gained through our previous work as well as literature 
reports, the objectives of the present work were to investigate the ability of IVIVCs to predict the in vivo 
burst release based on the in vitro burst release of formulations, and to evaluate whether IVIVCs 
developed based on high burst release microsphere formulation(s) are able to predict the in vivo 
performance of microsphere formulation(s) with no or minimal burst release and vice versa. Two PLGA 
microspheres drug products with different physicochemical properties and drug release characteristics i.e. 
Risperdal Consta® (risperidone) and Lupron Depot® (leuprolide acetate) were investigated to provide a 
comprehensive understanding of the impact of burst release on the development and predictability of 
IVIVCs for complex parenteral microspheres. Compositionally equivalent risperidone and leuprolide 
acetate microsphere formulations with high as well as low in vitro burst release were prepared through 
manufacturing process changes and characterized for various physicochemical properties and release 
characteristics under in vitro and in vivo conditions. Level A IVIVCs with the ability to predict the 
complete release profiles including variable burst release phase, were developed and validated in terms of 
internal as well as external % prediction error for Cmax and AUC 0-last for the microspheres products 
investigated. 
5.2. Material and methods: 
5.2.1. Materials  
PLGA (Resomer® 7525 DLG 6E and Resomer® Select 7525 DLG 2CA) were purchased from Evonik 
(Birmingham, AL). Risperidone was purchased from Jai Radhe, India. Leuprolide acetate (LA) and 
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reference standard (i.e. LHRH acetate salt) were purchased from Bachem Americas, Inc (Torrance, CA). 
Poly(vinyl alcohol) (PVA, M. Wt. 30–70 kDa), trifluoroacetic acid (TFA), and reference standards (i.e. 
risperidone, and risperidone-D4) were purchased from Sigma-Aldrich (St. Louis, MO). Methylene 
chloride, methanol, acetonitrile (ACN, HPLC grade) and dimethyl sulfoxide (DMSO, ACS grade) were 
purchased from Fisher Scientific (Pittsburgh, PA). ). LC-MS grade 0.1% v/v formic acid in water, 0.1% 
v/v ammonium acetate in water, acetonitrile and methanol were purchased from VWR (Radnor, PA). 
Milli-Q® water was used for all studies. All other chemicals were obtained commercially as analytical-
grade reagents. 
5.2.2. Preparation of microspheres  
5.2.2.1. Risperidone microspheres  
PLGA with a similar molecular weight as that used in the commercial product Risperdal Consta® was 
used to formulate compositionally equivalent risperidone microspheres with manufacturing differences 
(e.g. homogenization, vortex mixing, and different solvents). Briefly, when methylene chloride (DCM) 
was used as the solvent, both PLGA and risperidone (polymer/drug, 4/3 (w/w)) were dissolved in DCM 
and mixed with other cosovlents (Table 3). The polymer/drug solution was then dispersed into an 
aqueous PVA solution (1%, w/v) saturated with DCM to form an oil-in-water (o/w) emulsion via 
homogenization (3400 rpm, 2 min) (IKA® Works, Inc.). The microparticles were hardened via 
evaporation at room temperature for 3 h and then the solvent was further removed under vacuum. The 
resulting microspheres were collected, washed using distilled water and lyophilized. Different sieving 
procedures using 25 μm and 212 μm sieves for wet sieving (pre-lyophilization) and only 212 μm sieve for 
dry sieving (post-lyophilization) were used. When ethyl acetate (EA) and benzyl alcohol (BA) were used 
as the solvent system, PLGA was dissolved in EA (16.7%, w/w) and risperidone was dissolved in BA 
(24%, w/w), respectively. The polymer and the drug solutions were then mixed and transferred to the 1% 
(w/v) PVA solution (saturated with EA) to form oil-in-water (o/w) emulsion via homogenization (3400 
rpm, 30 s) or vortex mixing (1200 rpm, 10 s). The resulting emulsions were transferred to a solvent 
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extraction medium (2.5% (v/v) EA in water) and the solvent was extracted overnight at 4 °C. Following 
solvent extraction, residual organic solvents were removed under vacuum at room temperature, following 
which the microspheres were collected and washed using an aqueous alcoholic solution (25% ethanol, 
v/v). The resulting microspheres were wet sieved using 25 μm and 212 μm sieves and lyophilized.  
5.2.2.2. Leuprolide acetate microspheres 
PLGA (M.wt. ~15KDa) with a similar molecular weight as that used in the commercial product 
Lupron Depot® was used to formulate compositionally equivalent LA microspheres using different 
manufacturing processes. Briefly, 200 mg of PLGA were dissolved in methylene chloride (45%, w/v). LA 
is poorly soluble in methylene chloride and accordingly, a co-solvent (such as methanol, benzyl alcohol, 
and DMSO (Table 4)) was used to facilitate dissolution of LA. The LA solution was added to the 
polymer solution to form the organic phase and mixed by vortexing. The organic phase containing both 
the polymer and drug was then dispersed into a 0.35% (w/v) PVA solution to form an oil-in-water (o/w) 
emulsion using a homogenizer ((IKA® Works, Inc.) set at 14,000 rpm for 10 seconds followed by 13,000 
rpm for 90 seconds. Leuprolide acetate microspheres with large particle size were prepared using a lower 
emulsification/size reduction force (homogenization at 9000 rpm for 10 seconds followed by 8000 rpm 
for 90 seconds). The resultant o/w emulsion was stirred at 400 rpm for 3 h under vacuum at room 
temperature to allow microsphere solidification and solvent evaporation. The resultant microspheres were 
collected, washed using distilled water, and lyophilized. The resulting dry microspheres were sieved 
using 75 μm sieve. 
5.2.3. Characterization of microspheres  
5.2.3.1. High performance liquid chromatography (HPLC) analysis 
5.2.3.1.1. Risperidone microspheres: 
The quantification of risperidone was conducted using a Perkin Elmer HPLC system (series 200) with 
a UV absorbance detector set at 275 nm. A mobile phase consisting of acetonitrile/water/TFA (30/70/0.1, 
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v/v/v) at a flow rate of 1 mL/min and a Kinetex C18 column (250 × 4.6 mm, 5 μm, 100 Å) column were 
used. The sample injection volume was 10 µL for drug loading and 50 µL for in vitro release testing 
sample analysis. The chromatographs were analyzed using a PeakSimple™ Chromatography System (SRI 
instruments, Torrance, CA). 
5.2.3.1.2. Leuprolide Acetate microspheres: 
The quantification of LA was conducted using an Agilent HPLC system (series 1200) with a UV 
absorbance detector set at 220 nm (release test samples)/280 nm (drug loading test samples). A mobile 
phase consisting of 0.1% (v/v) trifluoroacetic acid in water (A) and Acetonitrile (B) was used for 
separation of LA through gradient elution (Table 1) at 30°C. A Kinetex® EVO C18 column (250 x 4.6 
mm, 5μm, 100Å, Phenomenex) was used as the stationary phase. The sample injection volume was 20 µL 
for drug loading and 50 µL for in vitro release test sample analysis. The chromatographs were analyzed 
using a Agilent OpenLAB chromatography data system.  
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5.2.3.2. Drug loading  
Five milligrams of the both the microspheres were weighed and transferred into 10 mL volumetric 
flasks. DMSO (2.5 mL for risperidone and 2 mL for LA) was added into the volumetric flasks and the 
samples were sonicated until all particles were dissolved. Methanol was added upto the 10 mL mark to 
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dilute the sample. The solution was filtered (Millex® HV, 0.22 μm PVDF syringe filter) and the drug 
concentration was determined with a validated HPLC assay method as described above. All the 
measurements were conducted in triplicate and the results are reported as the mean ± SD. Drug loading 
was calculated as:  
Drug Loading (%)= 
weight of drug entrapped
weight of microspheres analyzed
 × 100 
5.2.3.3. Particle size and particle size distribution  
Particle size and particle size distribution of both the microspheres were measured using an 
AccuSizer autodiluter particle sizing system (Nicomp, Santa Barbara, CA). Briefly, microspheres were 
dispersed in 0.1% (w/v) PVA solution in water to ensure good dispersion, and then particle size analysis 
was conducted. All the measurements were conducted in triplicate and the results are reported as the 
5.mean ± SD. 
5.2.3.4. Differential scanning calorimeter (DSC) analysis  
The glass transition temperatures (Tg) of both the microspheres were analyzed using a modulated 
temperature differential scanning calorimeter (MTDSC) (TA Instruments Q2000). Briefly, weighed 
quantity (~ 5-6 mg) of each sample was transferred to standard aluminum pans and sealed with aluminum 
lids. The DSC experiment was performed using a 2°C/min heating rate and a modulation amplitude of 
± 0.82°C with an 80 s modulation period. All samples were subjected to a heat/cool/heat cycle. The 
results were analyzed using TA analysis software, and the Tg was determined as the glass transition 
midpoint in the reversing signal. The crystallinity of risperidone was also investigated.  
5.2.3.5. Morphology  
The morphology of the commercial product and the prepared microspheres was characterized using 
scanning electron microscopy (SEM). Briefly, dry microspheres were mounted on carbon taped 
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aluminum stubs and sputter coated with gold. The samples were analyzed using SEM (NanoSEM 450, 
Nova). 
5.2.3.6. Porosity  
The porosity of the microspheres was determined using a Mercury Porosimeter (AutoPore IV 9500, 
Micromeritics). Briefly, approximately 200 mg samples of the microspheres were introduced into the 
porosimeter and tested at a mercury filling pressure of 0.53 psi. Total % porosity and average pore 





5.2.3.7. Molecular Weight (M. Wt.) 
The molecular weight of both the microspheres was determined by gel permeation chromatography 
(GPC; Waters) with an evaporative light scattering detector (ELSD). The mobile phase was 
tetrahydrofuran (THF) with a flow rate of 2 mL/min at 40◦C. Sample solutions in tetrahydrofuran (THF) 
at a concentration of 1 mg/mL were filtered through a 0.45 μm filter (Millipore, USA) before injection 
into the GPC system. The data collection and analysis were performed using Waters Millenium software. 
Polystyrene standards (2000, 900, 824, 400, 200, 110, 43, 18.80, 17.60, 6.93, 2.61, 0.98 kDa) were used 
for calibration and weight average molecular weights (M. Wt.) were calculated. All measurements were 
conducted in triplicate and the results are reported as the mean ± SD.  
5.2.4. In vitro release studies 
5.2.4.1. Risperidone microspheres 
In vitro release testing of the risperidone microspheres was investigated using the previously 
developed USP apparatus 4 method [15]. Briefly, the microspheres (10 mg) were mixed with glass beads (1 
mm) and placed in the USP apparatus 4 dissolution cells. PBS (10 mM, pH 7.4, 250 mL) with 0.01% 
(w/v) sodium azide was circulated through the flow through cells at a flow rate of 8 mL/min at 37 °C. At 
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pre-determined time intervals, 1 mL samples were withdrawn and replenished with fresh media. The 
release samples were analyzed via HPLC.  
2.4.2. Leuprolide Acetate microspheres 
In vitro release testing of the LA microspheres was conducted using a previously developed sample-
and-separate method at 37°C (11). Briefly, 6 mg of microspheres were dispersed in 1 mL of phosphate 
buffered saline (PBS containing 0.02% (v/v) Tween 20 and 0.02% (w/v) sodium azide, 33mM, pH 7.4) in 
low protein binding eppendorf tubes mounted on a rotator set at 100 rpm and incubated at 37 °C. At pre-
determined time intervals, the release media were collected and centrifuged at 3,000 rpm for 3 min. 
Supernatants (0.3 mL) were filtered through 0.22 μm filters and analyzed via HPLC. The release medium 
was replaced with fresh media at each sampling time point.  
Media replacement during release testing was taken into account in the calculation of the % 
cumulative release. All drug release tests were conducted in triplicate and the results are reported as the 
mean % cumulative release ± SD. 
5.2.5. In vivo release studies of microspheres 
In vivo release characteristics of both the risperidone and LA microspheres were investigated using a 
rabbit model. Briefly, rabbits were randomLy assigned to cages and treated with the prepared microsphere 
formulations and the commercial product (n = 6). The microspheres were suspended in the diluent used 
for dispersion of commercial products prior to injection. The suspended microspheres were injected into 
the rabbit hind leg thigh muscle (dose: 1.92 mg/kg for risperidone and 2.14 mg/kg for LA) and blood 
samples were collected from the marginal ear veins at predetermined time intervals. The collected blood 
samples were centrifuged for 5 min at 14,500 rpm and plasma was collected and stored at −20°C until 
analysis. Risperidone and LA were extracted from the plasma samples and analyzed via LC-MS/MS. The 
animal study protocol was reviewed and approved by the University of Connecticut's Institutional Animal 
Care and Use Committee (IACUC) prior to beginning the experiments.  
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5.2.6. Plasma sample analysis 
5.2.6.1. Risperidone  
Risperidone was extracted from plasma using tert-butyl methyl ether15. Risperidone-D4 was used as 
an internal standard (IS). Briefly, the internal standard solution (100 ng/mL, 20 μl) was added into 200 μl 
of plasma samples. Then tert-butyl methyl ether (1.1 mL) was added into the plasma samples and vortex-
mixed for 10 min followed by centrifugation at 14,000 g (4 °C) for 5 min. The supernatants were 
transferred to the polypropylene centrifuge tubes and dried under nitrogen at 40 °C. The dry residues were 
reconstituted in 100 μl of mobile phase (0.1% formic acid in water/methanol: 80/20 (v/v)) and analyzed 
using a previously developed LC–MS/MS analytical method15.  
Chromatographic separations were carried out on a Kinetex Biphenyl column (50 × 2.1 mm, 2.6 μm, 
100 Å) through gradient elution of mobile phase at 0.3 mL/min and 40 °C. Mobile phase A was 0.1% 
formic acid in water (LC–MS); mobile phase B was methanol (LC–MS). The gradient started at 80% 
mobile phase A and was decreased to 5% over 8 min, then held constant for an additional 1 min. At 10 
min, the column was returned to 80% mobile phase A and re-equilibrated for 8 min. The MS detection 
parameters were: 3500 V electrospray voltage, 300 °C capillary temperature, and 30 V collision energy. 
Detection of ions was conducted in the positive-ion selected reaction monitoring mode with the following 
transitions: m/z 411.1 → 195.1 for risperidone, and m/z 415.1 → 195.1 for risperidone D4. The injection 
volume was 10 μl. The data acquisition was ascertained by Xcalibur software. The lowest limit of 
quantification (LLOQ) for risperidone was 0.517 ng/mL and the mean recovery of plasma samples from 
low to high concentrations of risperidone was more than 90%.  
5.2.6.2. Leuprolide Acetate 
LA ((Des-Gly10, D-Leu6, Pro-NHEt9)-LHRH), M.wt. 1209.42 Da) was extracted from plasma samples 
using a protein precipitation extraction method11. LHRH ((Des-Gly10, D-Ala6, Pro-NHEt9)-LHRH, M.wt. 
1167.34 Da) acetate salt was used as the internal standard (IS). Briefly, 100 μl plasma samples were 
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mixed with 100 μl drug solution in diluent (0.1% formic acid in water: acetonitrile (90:10, %v/v) for the 
preparation of calibration standards (1, 2.5 5, 10, 15, 20 and 30 ng/mL) or 100 μl of diluent for study 
samples. All samples were then spiked with 20 μl of the IS solution (200 ng/mL in methanol). Ice-cold 
acetonitrile was then added in a stepwise fashion (two-steps, each of 500 μl) to the pre-treated plasma 
samples and vortex-mixed for 10 minutes at 2,500 rpm followed by centrifugation at 14,500 rpm (4°C) 
for 8 minutes. The supernatants were transferred to the low-protein binding polypropylene (PP) centrifuge 
tubes and dried under nitrogen at 40°C. The dry residues were then reconstituted in 100 μl of diluent 
(0.1% formic acid in water/acetonitrile, 90:10 %v/v). 25 μl of the reconstituted solution was used for LC-
MS/MS analysis.  
Chromatographic separations were carried out on a Kinetex EVO C18 column (50 x 2.1 mm, 2.6 μm, 
100 Å) through gradient elution (Table 2) at 35°C. The following MS detection parameters were used: 
4400 V electrospray voltage, 320°C capillary temperature, and 35 V collision energy. Detection of ions 
was conducted in the positive-ion selected reaction monitoring mode with the following transitions in a 
single reaction monitoring (SRM) mode: m/z 605.5 to 249.1 for leuprolide acetate, and 584.67 to 249.1 
for the IS. The injection volume was 25 μl. The data acquisition was ascertained by Xcalibur software. 
Calibration curves were established on each day when analysis was conducted and showed good linearity 
with correlation coefficients > 0.99. The lowest limit of quantification (LLOQ) for LA was 1 ng/mL and 
the mean recovery of plasma samples from low to high concentrations of LA was more than 90%.  





0.1% formic Acid/0.1% ammonium 
acetate (21/, v/v), % 
ACN, % 
0 0.3 95 5 
5 0.3 40 60 
8 0.3 40 60 
 113 
9 0.3 95 5 
12 0.3 95 5 
 
5.2.7. Development of IVIVCs  
The relationship between fraction of drug released in vitro and the fration of drug absorbed in vivo from 
the prepared micropshere formulations was assessed using a two stage based deconvolution approach 
following the same principles as detailed in the U.S. FDA IVIVC guidance on extended release oral 
dosage forms1. Briefly, the in vivo plasma profiles of the prepared risperidone and LA PLGA 
microspheres were deconvoluted using the Loo–Riegelman method [16]. Standard errors are not shown in 
the deconvoluted in vivo profiles because the average plasma concentration values were used. The 








Cp, Ct, K10 and AUC are the drug concentration in the central compartment (plasma), apparent tissue 
compartment concentration, elimination rate constant and area under the plasma vs. time curve, 
respectively. The previously determined distributive and elimination micro rate constants (k12, k21 and 
k10) 10,15 were used for calculating Ct.  
2.8. Statistical analysis  
Statistical data analysis was performed using a paired student t-test.  The level of significance was 
accepted at p < 0.05. 
5.3. Results and Discussion: 
5.3.1. Physicochemical properties of the risperidone microspheres: 
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Compositionally equivalent risperidone microspheres with variable burst release were prepared using 
a single emulsion solvent evaporation method with minor manufacturing differences (Table 3). As shown 
in Table 3, all the formulations prepared using different manufacturing processes were optimized to have 
similar drug loading (~37 % w/w), which indicates that all the prepared formulations were 
compositionally equivalent. 
Table 3. Q1/Q2 equivalent risperidone microsphere prepared with manufacturing differences 
Formulation Solvent 
System/ratio 
Preparation Method % DL 




- - 39.42±1.92 43.97 ± 4.60 
High burst release formulations 
Formulation 1 DCM 
(1.2 g) 
Homogenization & dry 
sieving 
36.77±1.44 46.04 
Formulation 2 DCM 
(1.2 g) 
Homogenization & wet 
sieving 
37.67±0.94 43.19 
Formulation 3 DCM/EA 
(0.7/0.5 w/w) 
Homogenization & wet 
sieving 
38.20±0.89 61.01 
Low burst release formulations 
Formulation F4 EA/BA 
(1/0.42 w/w) 
Vortex & wet sieving 37.33±0.60 54.98 
Formulation F5 EA/BA 
(1/0.42 w/w) 
Homogenization & wet 
sieving 
36.45±1.23 61.75 
Formulation F6 DCM/BA 
(1/0.2 w/w) 
Homogenization & wet 
sieving 
36.69±2.89 48.43 
Formulation F7 DCM/Methanol 
(1/0.2 w/w) 




DCM - Dichloromethane;  EA - Ethyl Acetate; BA - Benzyl Alcohol 
As shown in Figure 1A, in terms of population distribution, formulation F1 had significantly lower 
size compared to the RLD product and formulations F2 and F3. This is probably a result of formulation 
F1 being prepared using a dry sieving procedure, which retains smaller particles (<25 um) that otherwise 
would be removed during the wet sieving procedure used for the other formulations.  In terms of volume 
distribution, no significant differences in particle size and size distribution were observed among the 
prepared formulations with high burst release phase and the RLD product. 
As shown in Figure 1B, formulation F4 had particle size and size distribution similar to the RLD 
product, Risperdal Consta®, but significantly different than the other prepared formulations, F5, F6 and 
F7. Compared to formulation F4, formulation F5 had lower particle size as it was prepared using a 
stronger homogenization force. Similarly, formulations F6 and F7 prepared using homogenization had 
lower particle size compared to F4 but only in terms of volume distribution. In terms of population 
distribution, formulations F6 and F7 had similar or higher particle size compared to F4. This may be due 
to the use of a lower solvent amount in the preparation of formulations F6 and F7 leading to increased 
polymer solution concentration and viscosity, which ultimately resulted in the formation of larger 
particles, of the same size as formulation F415. In addition, methanol has high viscosity compared to the 
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Figure. 1. Particle size and particle size distribution of Risperdal Consta® 
and the prepared risperidone microspheres A) High burst release 
formulations; B) Low burst release formulations. All values are expressed 
as mean ± SD (n = 3 batches); C) Factors affecting particle size of 
microspheres. 
As shown in Figure 2, risperidone formulations prepared using DCM based solvent systems (F1, F2, 
F6 and F7) were polydisperse and of spherical shape with smooth surfaces. On the other hand, the 
risperidone formualtions prepared using the EA/BA solvent system (i.e. formulations F3, F4 and F5) 
showed some irregular shapes and indentations, a morphology similar to that of Risperdal Consta®. 
These differences in morphology were further evaluated by determination of the porosity of these 
formulations. As shown in Table 3, the risperidone microspheres prepared using DCM as the solvent (i.e. 
Formulations F1, F2, F6 and F7) showed the lowest % porosity, indicating that these microspheres have a 
denser structure as indicated by the morphology. While formulation F3, F4 and F5 prepared with EA 
showed higher % porosity compared to the other formulations. This may be due to rapid evaporation of 
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boiling point EA and BA at 4°C during the microsphere solidification process. This, in turn, results in 
rapid polymer precipitation and hence, dense particles in the DCM based formulations compared to the 
EA/BA based formulations.  Slower solvent removal via extraction for EA/BA based formulations leads 
to dynamic solvent exchange during solidification resulting in water inclusion inside the microspheres, 
which generates pores upon solvent removal during lyophilization 11. No significant differences were 
observed in other physicochemical properties such as polymer molecular weight (~75 KDa) and Tg 
(~42°C) of all the prepared formulations. 
  
Figure 2: SEM images 
of morphology of 
Risperdal Consta® and 
the prepared risperidone 
microsphere 
formulations: A) High 
burst release 
formulations; and B) 
Low burst release 
formulations. 
 
5.3.2. Physicochemical properties of the leuprolide acetate (LA) microspheres: 
As shown in Table 4, despite the differences in the solvent systems used, all the prepared LA 
microsphere formulations had similar drug loading, which indicates that the prepared microsphere 
formulations are compositionally equivalent.  
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– High speed 
DCM/MeOH  
(2.6/1) 






8.55±0.08 52.65 712.7 
F3 
Homogenization 
– High speed 
DCM/BA 
(2.2/1) 






8.47±0.14 61.01 964 
F5 
Homogenization 
– High speed 
DCM/DMSO  
(3.7/1) 
8.14±0.01 56.48 814.1 
DCM – Dichloromethane; BA- Benzyl Alcohol, DMSO: Dimethyl Sulfoxide, MeOH: 
Methanol 
As shown in Figure 3, in terms of population distribution, the particle size of all the prepared LA 
formulations and the RLD product was similar with slight differences in the size distribution. While in 
terms of volume distribution, the particle size of all the prepared formulations was higher than that of 
Lupron Depot®. Despite the use of the same solvent system, the prepared formulations F1 and F4 had 
smaller volume mean size compared to formulations F2 and F5 due to the use of the high speed 
homogenization during emulsion preparation compared to that for formulation F2 11. In contrast to this, 
despite the differences in the solvent systems, formulations F1 and F2 had similar volume mean size as 




Figure 3. Particle size and particle size distribution of Lupron Depot® and the 
prepared LA microsphere formulations: A) Low burst release formulations; and B) 
High burst release formulations. All values are expressed as mean±SD (n = 3 
batches).  
As shown in Figure 4, some irregular shapes and a highly porous polymer matrix (indicated by the red 
arrow) were observed for the RLD product, Lupron Depot®. On the other hand, the prepared LA 
microspheres showed a spherical shape with a smooth surface. Compared to formulations F1 and F2, 
formulations F3, F4 and F5 showed a more porous structure.  This may be due to the slower removal of 
high boiling point BA and DMSO compared to lower boiling point MeOH11. The observed differences in 
the porous structure of the prepared microsphere formulations were further confirmed and quantified by 
evaluation of % porosity of the LA microsphere formulations. As shown in Table 4, differences in the % 
total porosity of the formulations were observed with F3 being the most porous and F2 being the least 
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In addition, significant differences in the pore diameter of all the prepared formulations (Table 4) 
were observed with F2 having the smallest pore diameter and F4 having the largest pore diameter. The 
large pore diameter of formulation F4 is probably due to use of high boiling point DMSO as a cosolvent 
compared to formulations F1 and F2, which were prepared using low boiling point MeOH as a cosolvent. 
In contrast to this, despite the use of the same cosolvent, the pore diameters of F2 and F5 were smaller 
than that of F1 and F4, respectively, which is probably a result of the difference in their size. The smaller 
size of formulation F1 and F4 results in a shorter diffusion distance and hence, faster solvent removal and 
polymer solidification leading to the formation of large pores 17. Moreover, all the prepared microspheres 
had a similar polymer molecular weight of ~ 13 KDa and Tg of ~ 42°C. 
 
Figure 4: SEM 
images of the 
morphology of 





differences.   
 
5.3.3. In vitro release testing of the risperidone microspheres: 
In vitro release profiles of the RLD product (Risperdal Consta®) and the risperidone microsphere 
formulations with high burst release are shown in Figure 5A. Overall, all the formulations showed similar 
release duration (~36 days) but different release characteristics such as variable burst release and lag 
phase. The RLD product showed the lowest burst release (~1%) followed by a lag-phase of three weeks 
and then a fast release phase up to day 37. Compared to the RLD product, formulations F1 and F2 showed 
a relatively high burst release (~10%) and shorter lag phase of about 17 and 20 days, respectively. 
Risperidone is soluble in DCM, and hence, it may diffuse out to the surface of the microspheres during 
solvent removal resulting in the relatively high burst release of formulations F1 and F2. Moreover, the 
observed differences in the lag phase duration and release rate of formulations F1 and F2 may be due to 
2 µm 3 µm 
Lupron Depot® F1 
F2 F3 
3 µm 3 µm 3 µm 3 µm 
3 µm 3 µm 






differences in their particle size15. Compared to all other formualtions, formulation F3 had the highest 
burst release followed by slow and continuous release with no lag phase. The high burst release of 
formulation F3 may be due to the insolubility of risperidone in EA resulting in precipitation of 
risperidone in the DCM/EA solvent system. In addition, risperidone is practically insoluble in water. 
These factors together may lead to deposition of the precipitated risperidone on the microsphere surfaces. 
Although the exact mechanism is unclear, similar results (high burst release) have been reported 
previously for other microsphere formulations prepared using such co-precipitation method18. 
The “real-time” release profiles of the risperidone microsphere formulations with low burst release 
and the RLD product are shown in Figure 5B. Overall, all the prepared formulations F3 to F7 had low 
burst release (~1%) similar to the RLD. However, they had a relatively shorter or no lag-phase with an 
overall shorter release duration of ~ 30 days compared to ~35 days for the RLD product. The low burst 
release of these formulations may be due to the use of cosolvents such as BA/MeOH leading to more 
distribution of drug inside the microspheres with less accumulation on their surfaces. Shorter overall 
release profiles of formulations F3 to F7 may be due to differences in drug distribution inside the 
microsphere formulations resulting from dissimilarities in drug solubility in solvent systems and the 
miscibility of the solvent system with water. For example, risperidone has better solubility in the 
DCM/BA or DCM/MeOH compared to the EA/BA solvent system since risperidone is not soluble in EA. 
Hence, risperidone will be able to diffuse along with DCM and distribute homogenously throughout the 
microsphere formulations F6 and F7 during solvent removal. On the other hand, risperidone may be 
entrapped in the center of microsphere formulations F4 and F5 prepared using the EA/BA solvent system 
instead of achieving a more homogenous distribution. Additionally, there were differences in the particle 





Figure 5. In vitro release profiles of the Risperdal Consta® and the prepared  risperidone 
microsphere formulations obtained using the USP apparatus 4 method: (A) High Burst 
release formulations; and (B) Low burst release formulations. 
5.3.4. In vitro release testing of the leuprolide acetate microspheres  
The in vitro release profiles of the RLD product, Lupron Depot® and the prepared leuprolide acetate 
microsphere formulations are shown in Figure 6. Overall, all the formulations appeared to follow 
biphasic release characteristics with variable burst release followed by an apparent zero-order release due 
to the slow desorption of positively charged peptide from the negatively charged acid end group of the 
polymer11. Formulations F4 and F5 (30-40%) had higher burst release, similar to the RLD product 
(~45%) while formulations F1, F2 and F3 had relatively low burst release phase (10-15%). The observed 
differences in the burst release of the prepared formulations are due to the differences in the solvent 
systems used (Table 4 ) (Figure 3)11. As discussed for risperidone microspheres, differences in the 
solvent systems lead to differences in the polymer precipitation rate and drug diffusion on to the surface 
of the microspheres. The rapid removal of DCM/MeOH under vacuum at room temperature, results in the 
faster polymer precipitation and entrapment of the drug inside the bulk of the microspheres compared to 
DCM/DMSO. Despite the similar lower burst release phase, formulation F2 had slower release compared 
to formulation F1. This may be a consequence of the higher particle size, lower porosity and average pore 






































37ºC, USP 4 (10 mM PBS, pH 7.4) (n=3) 












































37ºC, USP 4 (10 mM PBS, pH 7.4) (n=3) 









compared to formulation F4 due to its larger size. Compared to all other prepared LA formulations, 
formulation F3 (prepared using DCM/BA) was the slowest releasing formulation with a significantly 
lower release rate between days 10 and 20 despite the highest porosity and relatively larger average pore 
diameter. This might be due to particle aggregation in the presence of residual organic solvent resulting 
form the incomplete removal of high boiling point BA compared to cosolvents. Accordingly, the total 
release duration of formulation F3 was longer (~80 % release by day 45) compared to Formulations F1 
and F2 (~80 % release by day 38).  
  
Figure 6. In vitro release profiles of Lupron Depot®  and the prepared LA microsphere 
formualtions obtained using the sample and separate method: (A) Low burst release 
formulations; and (B) High burst release formulations. 
5.3.5. In vivo release testing of the risperidone microspheres 
In vivo release profiles of the RLD product and the prepared risperidone microsphere formulations 
with variable burst release are shown in Figures 7A and B. Overall, the in vivo release profiles of all 
risperidone formulations have the same rank order and similar release characteristics as that of the in vitro 
release profiles i.e. tri-phasic release profile with variable burst release, lag phase and fast releasing phase 
(Figures 5A and B). As shown in Figure 7A, the RLD product had the lowest initial plasma 
concentration with the longest lag phase of about 15 days. Formulations F1 and F2 had relatively high 
burst release in vitro and accordingly, high initial plasma concentrations with a shorter lag phase of about 
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initial plasma concentration followed by slow and continuous release till day 32 with no lag phase. The 
observed higher initial plasma concentration of all the prepared formulations, similar to the high in vitro 
burst release indicates that the absorption phase is not masking the bust release of the risperidone 
microspheres. This may be because risperidone is a lipophilic drug, practically water insoluble with low 
M.wt. and hence, it should have rapid absorption at the intramuscular injection site. As shown in Figure 
7B, all the risperidone formulations with low in vitro burst release had low initial plasma concentrations. 
Formulations F4 and F5 had a lag phase of about 5 days while Formulations F6 and F7 did not show any 
lag phase, similar to their respective in vitro release profiles.  
Please note that the in vivo lag phase and overall release duration of all the risperidone microsphere 
formulations were shorter compared to the respective in vitro release profiles. This may be due to faster 
polymer degradation as a result of the local in vivo environment such as localized pH, enzymes etc.  
 
 
Figure 7A. In vivo release of Risperdal Consta® and the prepared risperidone microspheres in a rabbit 
model (i.m., n=6): (A) Formulations with high burst release; and (B) Formulations with low burst 
release. 
5.3.6. In vivo release testing of the leuprolide acetate microspheres 
The in vivo release profiles of the RLD product, Lupron Depot® and the prepared LA microsphere 
formulations are shown in Figure 8. The RLD product had high initial plasma concentration similar 
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the prepared LA microsphere formulations showed relatively low initial plasma concentrations 
followed by slow and continuous zero–order release over a 40-day period, similar to the in vitro 
release characteristics (Figure 6). Moreover, the in vivo release profiles of all the LA microsphere 
formulations including the RLD products were shorter with faster release rates compared to their in 
vitro release profiles, as discussed above for risperidone microspheres. 
  
Figure 8. In vivo release profile of Lupron Depot® and the prepared leuprolide acetate 
microspheres in a rabbit model (i.m., n=6) ): (A) Formulations with low burst release; and (B) 
Formulations with high burst release. 
5.3.7. Development of IVIVCs: 
Development of IVIVCs was performed using a two-stage deconvolution approach with time 
scaling/shifting factors as described in the U.S. FDA guidance1.  
5.3.7.1. Deconvolution of the in vivo release profiles to the fraction absorbed 
The in vivo plasma concentration vs time (PK) profiles (i.m.) of the risperidone and LA microspheres 
were deconvoluted into the fraction absorbed vs time (Figue 9) using the Loo-Riegelman method [11,15,16.  
Overall, the in vivo release profiles of all the formulations had the same rank order as their respective in 
vitro release profiles: 1) risperidone microspheres with high burst release – F7>F6>F5> F4>RLD; 2) 
risperidone microspheres with low burst release – F3> F2> F1> RLD; 3) LA microspheres with low burst 
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deconvolved in vivo release from PLGA microspheres appeared to be faster compared to their in vitro 
release profiles, as discussed above. Apart from this, no other significant differences in the release 
characteristics, especially the burst release phase under in vitro and in vivo conditions were observed for 
risperidone microspheres. Whereas, in the case of LA microspheres, the in vivo release profiles of all the 
formulations including the RLD product showed significantly lower in vivo burst release (Figure 9C and 
D) compared to the respective in vitro burst release profiles. This indicates that absorption of LA at the 
intramuscular site is slow due to its hydrophilic nature and larger size compared to risperidone, resulting 
in the masking of the in vivo burst release of the LA microspheres. 
  
  
Figure 9. Deconvolved in vivo profiles (fraction absorbed/released) of the compositionally 
equivalent microspheres (deconvolved using the Loo-Riegelman method): (A) Risperidone 
microspheres – High burst release formulations, (B) Risperidone microspheres – Low burst release 



















































































































































with high burst release formulations. 
 
5.3.7.2. Establishment of IVIVC between in vitro and in vivo fraction released/absorbed 
In order to develop IVIVCs, different combinations with a minimum of two or three formulations with 
different release rates were used. For risperidone as well as LA microspheres, the formulations were 
grouped as low and high burst release to minimize the impact of variable burst release on the 
predictability of the developed IVIVCs15,19. In the case of LA microspheres, the RLD product, Lupron 
Depot®, with high burst release was used as an external formulation for the IVIVC developed using the 
high burst release formulations. Based on the knowledge obtained from our previous research on 
microspheres15,19, formulations on the extremes of the release profile range (for example, formulations F1 
and F3 for the risperidone microspheres with low burst release) were included in the combinations of 
formulations used to develop correlation models.  
First, the in vitro release profiles were simulated via model fitting using Origin Pro (data analysis 
software) to synchronize the sampling time interval with the in vivo release profiles. Due to the 
differences in the % burst release and release rate of the in vitro and deconvoluted in vivo release profiles, 
time scaling and time shifting factors (determined using a Levy plot - in vivo vs in vitro time for definite 
fraction released) were used to achieve a 1:1 correlation. In the case of risperidone microspheres, only one 
factor i.e. a time scaling factor of 1/1.85 for high burst release formulations and a time shifting factor of -
11 for low burst release formulations was used to compensate for differences in the in vitro and in vivo 
release rate. For LA formulations, two factors i.e. a time-scaling factor of 1/1.65 and a time-shifting factor 
of +1 were used to adjust for differences in the burst release and the release rate under in vitro and in vivo 
conditions, respectively. The same time-scaling/shifting factors were applied to all formulations in each 
group used for the development and validation of the IVIVCs. The fraction absorbed/released in vivo of 
the selected formulations was plotted against the fraction released in vitro at the respective time point to 
establish a correlation if any. A total of four different IVIVC models based on the different groups of 
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risperidone and LA microsphere formulations were developed as shown in Figure 10 A, C, E and G. 
Affirmative point-to-point correlation IVIVCs i.e. a Level A (as per the U.S. FDA guidance1) between the 
fractions released in vitro and the fractions released/absorbed in vivo were obtained for all the groups 
using a simple linear regression model (correlation coefficients greater than 0.95). Please note that all the 
developed IVIVCs were different as manifested by different slopes and intercepts due to the difference in 
the drug release characteristics of each group.  
These developed IVIVCs were then validated for their ability to predict in vivo profiles of the external 
formulation (one that was not used to develop the IVIVC model) using the respective in vitro release 
profile of the external formulation. As shown in Figure 10 B, D, F and H, the predicted in vivo profiles 
including burst release phase of each external formulation almost overlapped with the observed 
deconvoluted in vivo release profiles. 
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Figure 10. Level A IVIVCs developed using the Loo-Reigelman method 
for microsphere formulations with variable burst release: (A) IVIVC 1 
developed using risperidone micropshere formulations with high burst 
release, F2 and F3; (B) IVIVC 1 -  experimental and predicted in 
vivo release profiles of risperidone microsphere formulation F1; (C) 
IVIVC 2 developed using risperidone microsphere formulations with low 
burst reelase F5, F6 and F7;  (D) IVIVC 2 -  experimental and predicted in 
vivo release profiles of risperidone microsphere formulation F4; (E) 
IVIVC 3 for LA microsphere formulations with low burst release F1and 
F3; (F) IVIVC 3 -  experimental and predicted in vivo release profiles of 
LA microsphere formulation F2; (G) IVIVC 4 for LA microsphere 
formulations with high burst release F4 and F5; and (H) IVIVC 4 -  
experimental and predicted in vivo release profiles of Lupron Depot®. 
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The predictability of the IVIVCs were further confirmed by determination of the % prediction errors (PE) 
of the developed IVIVCs for Cmax and AUC0-last using WinNonlin®. As shown in Table 3, the average 
internal and external %PE for the AUC0-last and Cmax were within the recommended range of 10% or less 
for IVIVC 1 developed for risperidone microspheres with high burst release phase. In case of IVIVC 2, 
developed for the risperidone microspheres with low burst release phase, the average internal %PE was 
not within the acceptance criteria for Cmax. However, the external % PE was within the acceptance 
criteria for both Cmax and AUC0-last (Table 3). Similarly, in the case of IVIVC 3 for LA microspheres, the 
average internal %PE was not within the acceptance criteria for Cmax. However, the external % PE was 
within the acceptance criteria for both Cmax and AUC0-last (Table 3). Also, the average internal and 
external %PE for the AUC0-last and Cmax were within the recommended range of 10% or less (Table 3) for 
the IVIVC 4 developed for LA microspheres with high burst release phase. Thus, all four developed 
IVIVCs are acceptable in terms of their ability to predict the in vivo performance of the microspheres.  
Table 3. Validation of the developed IVIVCs for risperidone and LA microspheres  
 Cmax (μg/l) AUC0-last (μg/l * day) 
Validation Obs. Pred. %PE Obs. Pred. %PE 






3.10 230.62 215.25 6.23 
External (F1) 19.99 20.56 2.87 202.92 184.55 -9.05 
IVIVC 2 - Risperidone microspheres with low burst release 





External F4 39.98 41.27 3.24 237.09 228.05 -3.81 






31.49 65.15 63.05 14.89 
External (F1) 4.22 4.03 -4.40 66.97 60.95 -8.98 










0.49 10.35 9.07 69.03 62.48 -9.48 
 
Following this, in order to demonstrate the impact of significantly variable burst release on the 
predictability of the IVIVCs, the in vivo release profile of the RLD product, Risperdal Consta®  (with very 
low burst release) was predicted from its in vitro release profile using the IVIVC 1 and 2 models 
developed for the prepared risperidone microsphere formulations. As shown in Figure 11, the in vivo 
release profile of the RLD product was not predicted using the IVIVC 1 model but was predicted using 
the IVIVC 2 model. The differences in the predictability were further confirmed by the determination of 
%PE. As shown in Table 4, in case of IVIVC 1, %PE for Cmax (-0.1%) was within the acceptance criteria 
of 10% but that of the AUC0-last (-28.81%) was higher than 10%. While in the case of IVIVC 2, both 
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%PEs for Cmax (10.30%) and AUC0-last (-0.70%) were within the acceptance criteria of 10%. This is 
because IVIVC 2 was developed using the formulations with low burst release similar to the RLD 
product, unlike IVIVC 1, which was developed using formulations with relatively high burst release. 
Accordingly, IVIVC 1 was not able to predict the in vivo profiles of the prepared risperidone formulation 
F4 with low burst release (Figure 11), with %PE for Cmax and AUC0-last higher than 10% (Table 4). 
Similarly, IVIVC 2 developed using the risperidone formulations with low burst release phase was not 
able to predict the in vivo profiles of the prepared risperidone formulation F3 with high burst release 
(Figure 11), with %PE for Cmax higher than 10% (Table 4).  
The impact of variable burst release phase on the predictability of the IVIVCs developed for LA 
microspheres was investigated to determine the influence of molecular properties 
(hydrophobicity/hydrophilicity and molecular weight) on the predictability of IVIVCs of such complex 
drug products. As shown in Figure 11, the in vivo release profile of the RLD product, Lupron Depot®  
(with very high burst release) was not predicted using IVIVC 3 developed using formulations with low 
burst release phase. The differences in the predictability were further confirmed by determination of the 
%PE. As shown in Table 4, in case of IVIVC 3, %PE for a AUC0-last (4.21%) was within the acceptance 
criteria of 10% but that of the Cmax (40.06%) was higher than 10%. Similarly, IVIVC 4, developed using 
the LA formulations with high burst release phase, was not able to predict the in vivo profiles of LA 
formulation F3 with low burst release (Figure 11) as confirmed by the %PE for Cmax and AUC0-last being 
higher than 10% (Table 4).  
These results suggest that significant variation in the burst release phase compromises the ability of the 
IVIVCs to predict the in vivo performance of microspheres and accordingly, IVIVCs for microspheres 





Figure 11. Experimental vs predicted in vivo release profiles obtained 
using the respective developed IVIVCs.  - Risperdal Consta®, prepared 
risperidone micropsheres and Lupron Depot® and prepared LA 
micropsheres. 
 
Table 4. Predictability of the developed IVIVCs for the Risperdal Consta®  
 Cmax (μg/l) AUC0-last (μg/l * day) 














































Predictability of IVIVC 2 























F4 _In Vivo 







































































IVIVC 1 – Risperidone microspheres with high burst release 
Risperdal 
Consta® 
38.29 37.32 -0.10 247.14 175.93 -28.81 
F4_Low 
burst 
39.98 31.42 -21.39 237.09 162.72 -31.37 
IVIVC 2 - Risperidone microspheres with low burst release 
Risperdal 
Consta® 
38.29 39.51 10.30 247.14 245.42 -0.70 
F3_High 
burst 
43.94 61.54 40.06 288.33 300.46 4.21 
IVIVC 3 – LA microspheres with Low burst release phase 
Lupron 
Depot® 
9.49 10.58 11.48 69.03 62.36 -11.11 
IVIVC 4 – LA microspheres with High burst release phase 
F3_Low 
burst 
3.53 5.36 51.50 75.42 65.68 12.91 
 
5.4. Conclusions: 
Affirmative level A IVIVCs were developed for the first time with the ability to predict in vivo release 
characteristics including high as well low burst release phase for parenteral microspheres containing two 
different therapeutic molecules. It was shown that developing IVIVCs using formulations with less 
variation in the burst release phase significantly improved their ability to accurately predict the drug 
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release characteristics, specifically the burst release phase of microspheres. However, it was also shown 
that the complexity and predictability of IVIVCs is sensitive to the type of burst release phase and hence, 
IVIVCs developed using a low burst release phase can not be used to predict formulations with high burst 
release and vice versa. This may limit the application of the IVIVCs to serve as a surrogate only for 
complex drug products with similar burst release phases. This work has provided a comprehensive 
understanding on the significance of variable burst release on the development and predictability of 
IVIVCs for microsphere drug products. This moves the field a step closer towards the development of 
IVIVCs in human for such complex parenteral drug products.  
Together with our previous research on developing a Level A IVIVCs for polymeric microspheres 
containing small molecules and peptides, it can be concluded that Level A IVIVCs can be developed for 
complex parenteral microsphere drug products using in vitro release testing methods and a rabbit model. 
This highlights the potential of developing IVIVCs using clinical data for such complex parenteral drug 
products, which can serve as a surrogate for bioequivalence studies. 
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The present work describes for the first time that Level A IVIVCs can be developed for 
variety of compositionally equivalent parenteral PLGA microsphere products (containing small 
molecule as well as large molecular weight and complex molecules such as peptides) with 
different physicochemical properties and drug release characteristics. It was observed that a 
combination of formulations with significant variation in the release rate as well as burst release, 
have the potential to alter the complexity and predictability of the IVIVC models. Hence, 
IVIVCs of parenteral PLGA microspheres should be developed using formulations that cover a 
wide range of release rates but with less variation in their burst release phase.  Also, the slow 
absorption of peptide at the intramuscular site showed the potential to mask the high burst 
release that is observed under in vitro release testing conditions, which in turn complicates the 
development of IVIVCs for such products. Thus, fundamental and comprehensive understanding 
on the development, complexity and predictability of IVIVCs for parenteral polymeric 
microspheres was achieved by investigating three different types of microsphere products. The 
development of Level A IVIVCs for complex parenteral microsphere drug products using a 
rabbit model highlights the feasibility of developing IVIVCs using clinical data to serve as a 
surrogate for bioequivalence studies. 
The present work also describes that the minor manufacturing changes (solvent systems, 
mixing methods/speed/time, solvent removal process) have the potential to alter the 
physicochemical properties (particle size, porosity, drug distribution), as well as drug release 
characteristics (release rate, duration) and hence, in vivo performance of a variety of 
compositionally equivalent parenteral PLGA microsphere drug products. This is significant for 
high-risk products such as microspheres containing a substantial amount of potent drugs. The 
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comprehensive evaluation of two different types of products has helped to identify critical 
quality attributes that have the potential to alter the drug release characteristics of Q1/Q2 
equivalent microspheres. It was also determined that additional CQAs may need to be 
investigated for peptide microspheres such as pore diameter/pore structure, emphasizing the need 
to establish product specific CQAs. The identified CQAs can be used as in vitro characterization 
tools to describe Q3 (microstructure) sameness of the Q1/Q2 equivalent PLGA microspheres. 
This knowledge will be helpful to regulatory authorities as well as the pharmaceutical industry 
during scale up, post approval manufacturing changes and for generic drug product development.  
Moreover, the developed USP apparatus 4 (naltrexone) as well as sample and separate 
(LA) based in vitro release testing methods have the potential to be used as a quality control 
tools to discriminate Q1/Q2 equivalent microspheres prepared with manufacturing differences 
and most importantly, as a bio-relevant method to predict the in vivo performance of these 
microspheres. The significant reduction in testing duration as well as discriminatory ability of the 
developed accelerated USP apparatus 4 release testing method shows its potential to be used as a 
quality control tool to assure product performance as well as assist in product development for 
naltrexone microspheres. 
Lastly, it was determined that the hydrolytic degradation kinetics of low molecular 
weight PLGA microspheres is not sensitive to differences in their particle size and porosity. 
However, the drug release characteristics of such microspheres containing relatively large 
hydrophilic molecules (peptides) were sensitive to changes in their pore structure/network.  
6.2. Future studies 
The Level A IVIVCs in the present work have been developed using an animal model 
(Rabbit). However, considering the interspecies differences between animals and humans, 
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further investigation is necessary to determine whether an IVIVC can be developed using clinical 
data. Moreover, it will be helpful to explore the application of the developed IVIVCs for the 
prediction of in vivo performance of compositionally equivalent microspheres prepared with 
changes in formulation parameters, polymer source variations etc. 
Our research on PLGA based in-situ forming implants has shown that polymer source 
variation can lead to significant changes in drug release characteristics. Based on these findings 
as well as the knowledge gained from the present work on the sensitivity of PLGA microspheres 
to minor changes in manufacturing processes, it is critical to investigate that impact of polymer 
source variations (minor changes in polymer characteristics such as lactic to glycolic acid ratio, 
random monomer sequences as well as microstructure) on any alterations of drug release 
characteristics of Q1/Q2 equivalent parenteral PLGA microspheres in order to ensure their 
consistent performance and safety.  
The present work also suggested that differences in drug distribution in the PLGA 
microspheres has the potential to alter drug release characteristics. Accordingly, it will be 
essential to investigate the drug distribution for such complex drug products using advanced 
characterization techniques with an ability to determine elemental distribution. 
 
 
 
 
